var title_f8_41_8848="Defibrillator pad placement PI";
var content_f8_41_8848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Defibrillator pad placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hands-free defibrillator patches placed in the anterior (white lead) and lateral (red lead) positions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Taylor C, Lillis C, LeMone P, Lynn P. Fundamentals of Nursing, The Art And Science Of Nursing Care, 6th Ed. Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8848=[""].join("\n");
var outline_f8_41_8848=null;
var title_f8_41_8849="Nimotuzumab: International drug information";
var content_f8_41_8849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nimotuzumab: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      TherCIM (AR, CN, CO, CU, IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F4145749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      TheraCIM hR3;",
"     </li>",
"     <li>",
"      Theraloc",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4145750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Monoclonal Antibody",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Epidermal Growth Factor Receptor (EGFR) Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4145751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nasopharyngeal and head and neck cancer; high-grade glioma in children and adolescents (investigational)",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4145753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Refer to individual protocols:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children: Glioma (investigational use): 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /week as a weekly infusion for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: 100-200 mg/week for 6 weeks with radiation",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10514 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-197.136.42.3-BE723D6DBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8849=[""].join("\n");
var outline_f8_41_8849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302620\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4145749\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4145750\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4145751\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4145753\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821102\">",
"      Product Availability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10514\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10514|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_41_8850="Cardiac plane definition";
var content_f8_41_8850=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Cardiac plane definition",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cardiac plane definition and display for tomographic imaging modalities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105:539. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8850=[""].join("\n");
var outline_f8_41_8850=null;
var title_f8_41_8851="Pectus severity index";
var content_f8_41_8851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Measurement of the pectus severity index",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 497px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pectus severity index (PSI) in a normal chest (PSI = 2.0) and in a patient with severe pectus excavatum (PSI = 3.5).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Oscar H Mayer.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8851=[""].join("\n");
var outline_f8_41_8851=null;
var title_f8_41_8852="Merkel cell carcinoma - face";
var content_f8_41_8852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Merkel cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This blue-red, dome-shaped papule on the forehead is a Merkel cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8852=[""].join("\n");
var outline_f8_41_8852=null;
var title_f8_41_8853="DAH PA I";
var content_f8_41_8853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61736%7EPULM%2F73492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61736%7EPULM%2F73492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse alveolar hemorrhage in isolated capillaritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph from a patient with diffuse alveolar hemorrhage due to isolated pulmonary capillaritis. Note the&nbsp;bilateral&nbsp;ground glass opacities&nbsp;and normal heart size.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marvin I Schwarz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse alveolar hemorrhage due to inhalation of crack cocaine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph from a patient with diffuse alveolar hemorrhage due to inhalation of crack cocaine showing patchy upper zone opacities. The radiograph returned to normal in several days without specific treatment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marvin I Schwarz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8853=[""].join("\n");
var outline_f8_41_8853=null;
var title_f8_41_8854="Clozapine: Patient drug information";
var content_f8_41_8854=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clozapine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     see \"Clozapine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/31/13817?source=see_link\">",
"     see \"Clozapine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Clozaril&reg;;",
"     </li>",
"     <li>",
"      FazaClo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clozapine&reg;;",
"     </li>",
"     <li>",
"      Clozaril&reg;;",
"     </li>",
"     <li>",
"      Gen-Clozapine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700484",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe blood cell problems may happen. Report any fever, sore throat, mouth sores, infections, easy bruising, or purple \"splotches\" on your skin to your doctor right away. Follow what the doctor tells you about blood tests while taking this drug. These tests are needed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700314",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of seizures, head injury, or brain tumor, your chance of having a seizure may be higher if taking a large dose of this drug every day. Stopping some drugs all of a sudden, a sudden change in drinking alcohol, or taking some drugs may raise the chance of seizures. Check all drugs with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700332",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause harm to your heart sometimes. It may cause low blood pressure or a fast heartbeat. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a higher chance of death in older adults who take this drug for mental problems caused by dementia. Most of the deaths were linked to heart disease or infection. This drug is not approved to treat mental problems caused by dementia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat schizophrenia. It may take 6 weeks to see the full effect.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691747",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat problems with how one acts.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701847",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to clozapine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bowel block, low white blood cell count, or seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697327",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. The oral-disintegrating tablet has phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697355",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you smoke, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drooling when sleeping.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the heart may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705488",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not push the tablet out of the foil when opening. Use dry hands to take it from the foil. Place on your tongue and let it melt. Water is not needed. Do not swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3452339",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you miss 2 or more days of this drug, call your doctor to find out how to restart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use oral-disintegrating tablet right after opening. Throw away any part of opened pouch that is not used.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12336 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-47B75F185E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8854=[""].join("\n");
var outline_f8_41_8854=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153952\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153953\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029042\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029044\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029043\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029048\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029049\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029051\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029046\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029047\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029052\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029053\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=related_link\">",
"      Clozapine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/31/13817?source=related_link\">",
"      Clozapine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_41_8855="Approach to adjuvant treatment of endometrial cancer";
var content_f8_41_8855=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to adjuvant treatment of endometrial cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/41/8855/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/41/8855/contributors\">",
"     Steven C Plaxe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/41/8855/contributors\">",
"     Arno J Mundt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/41/8855/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/41/8855/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/41/8855/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/41/8855/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/41/8855/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1596994125\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of endometrial cancer following surgical staging is based on the risk of relapse and persistent disease, which is defined by the cancer stage at diagnosis and presence of prognostic factors. This topic will cover the risk stratification criteria for newly diagnosed endometrial cancer. The treatment by risk category is covered separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=see_link\">",
"       \"Treatment of low-risk endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13287?source=see_link\">",
"       \"Adjuvant treatment of intermediate-risk endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41991?source=see_link\">",
"       \"Adjuvant treatment of high-risk endometrial cancers\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1596994160\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION AND OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Joint Committee on Cancer (AJCC) and International Federation of Gynecology and Obstetrics (FIGO) combined staging system is used to designate cancer stage (",
"    <a class=\"graphic graphic_table graphicRef51307 \" href=\"UTD.htm?42/33/43549\">",
"     table 1",
"    </a>",
"    ). In addition to stage, other pathologic factors are used to determine risk of recurrent or persistent disease. The risk stratification scheme and a brief overview of adjuvant treatment recommendations, modeled after the criteria of the Gynecologic Oncology Group (GOG), are discussed below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1596994167\">",
"    <span class=\"h2\">",
"     Low-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with low grade (grade 1 or 2) endometrioid cancers confined to the endometrium (a subset of stage IA disease) are classified as having low-risk endometrial cancer. The overall probability of recurrence in these groups is very low following surgical treatment alone. There is no evidence to support benefit from adjuvant therapy for patients with low-risk or low intermediate-risk disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=see_link\">",
"     \"Treatment of low-risk endometrial cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215731639\">",
"    <span class=\"h2\">",
"     Intermediate-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at intermediate risk are identified based on the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer that is confined to the uterus but invades the myometrium (stage IA or IB) or demonstrates occult cervical stromal invasion (stage II). These groups have a higher risk of recurrence than do patients whose tumors are confined to the endometrium (which defines patients with low-risk endometrial cancer).",
"     </li>",
"     <li>",
"      Other adverse prognostic factors are used to stratify women with intermediate-risk endometrial cancer: outer one-third myometrial invasion, grade 2 or 3 differentiation, or the presence of lymphovascular invasion within the cancer. These criteria are used to further stratify women into high- and low-intermediate risk groups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      High-intermediate risk &ndash; This is based on a combination of age and number of prognostic factors present:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients of any age with all three factors",
"     </li>",
"     <li>",
"      Patients 50 to 69 years old with two factors",
"     </li>",
"     <li>",
"      Patients 70 years or older with only one factor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the absence of the criteria for high-intermediate risk, all others in this category are considered to be at low intermediate risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intermediate-risk patients have an increased risk of locoregional relapse in the presence of high risk factors, but overall they are at low risk of distant metastases. As such, these women benefit most from postoperative RT.",
"   </p>",
"   <p>",
"    Some clinicians offer adjuvant chemotherapy (with or without RT) to women with high-intermediate risk endometrial cancer, although the benefit of this approach is not clear. We prefer to offer patients treatment on clinical trials. These patients are candidates for Gynecologic Oncology Group Trial 249 (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00807768\">",
"     GOG 249",
"    </a>",
"    ), a phase III trial of pelvic RT or vaginal brachytherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13287?source=see_link\">",
"     \"Adjuvant treatment of intermediate-risk endometrial cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1596994188\">",
"    <span class=\"h2\">",
"     High-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The features that identify women with endometrial cancer at high-risk are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage III disease, regardless of histology or grade",
"     </li>",
"     <li>",
"      Uterine serous carcinoma (USC) or clear cell carcinoma (CC) of any stage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given their high risk of relapse and death from endometrial cancer, women with high-risk endometrial cancers often receive adjuvant chemotherapy. However, the optimal regimen and the role that RT has to improve survival outcomes are unclear. Whenever possible, we believe these patients should be offered participation in appropriate clinical trials. Patients with high-risk endometrial cancer are candidates for",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00942357\">",
"     GOG 258",
"    </a>",
"    , a phase III trial of chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41991?source=see_link\">",
"     \"Adjuvant treatment of high-risk endometrial cancers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215731739\">",
"    <span class=\"h2\">",
"     Other factors that affect risk",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215731542\">",
"    <span class=\"h3\">",
"     Lower uterine segment involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with otherwise low-risk disease who have involvement of the lower uterine segment may be at a greater risk for nodal involvement. However, it is not clear if involvement of the lower uterine segment represents an independent risk factor for survival. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=see_link\">",
"     \"Treatment of low-risk endometrial cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215731098\">",
"    <span class=\"h3\">",
"     Positive peritoneal cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 11 percent of patients undergoing surgical staging have positive peritoneal cytology, most commonly in the setting of advanced (extrauterine) disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/1\">",
"     1",
"    </a>",
"    ]. However, positive peritoneal cytology is no longer considered in the staging system for endometrial carcinoma to assign tumor (T) stage (",
"    <a class=\"graphic graphic_table graphicRef51307 \" href=\"UTD.htm?42/33/43549\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic significance of isolated positive peritoneal washings in the absence of extrauterine spread remains controversial, as illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2009 systematic review that included over 50 studies reported that the prognosis associated with a positive peritoneal cytology varied according to the presence of other factors [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/3\">",
"       3",
"      </a>",
"      ]. Women with positive peritoneal cytology, but otherwise low-risk disease (grade 1 or 2, myometrial invasion &lt;50 percent, no cervical involvement, no lymphovascular space invasion) had a significantly lower rate of recurrence compared with other women (4.1 versus 32 percent).",
"     </li>",
"     <li>",
"      However, a 2012 analysis of 14,704 patients identified from the Surveillance, Epidemiology and End Results (SEER) registry reported that positive peritoneal cytology was an independent predictor of mortality, regardless of histologic subtype, among women with early stage (stage I to II) endometrial carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/4\">",
"       4",
"      </a>",
"      ]. The main results were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with high-risk factors (eg, grade 3 disease, clear cell or serous histology) were more likely to have positive peritoneal cytology than those without high-risk factors (17.5 versus 7.5 percent, respectively, p&lt;0.0001).",
"     </li>",
"     <li>",
"      The presence of positive peritoneal cytology predicted significantly poorer survival regardless of histology and tumor grade compared to those with negative cytologic results.",
"     </li>",
"     <li>",
"      The risk of death was significantly higher among women with positive peritoneal cytology compared to those with negative peritoneal cytology and stage IA disease (HR 4.6, 95% CI 3.79-5.66).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We do not routinely consider peritoneal cytology results by itself in the formulation of a treatment plan for patients with endometrial cancer and continue to make treatment decisions primarily based on extent of disease (determined at staging) and final pathologic features. We agree with the 2009 International Federation for Gynecologic Oncology (FIGO) staging guidelines for endometrial cancer and report cytology results separately without adjustment to the T-stage [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link&amp;anchor=H6#H6\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\", section on 'Staging and primary surgical treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215731105\">",
"    <span class=\"h3\">",
"     Influence of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older age has been associated with higher rates of clinical failure and survival in several [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/6-11\">",
"     6-11",
"    </a>",
"    ] (but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/12\">",
"     12",
"    </a>",
"    ]) studies. The association between age and prognosis can be illustrated by data from GOG protocol 33, in which five-year relative survival rates for women with clinical stage I and II endometrial cancer stratified by age were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &le;40 years old &mdash; 96 percent",
"     </li>",
"     <li>",
"      41 to 50 years old &mdash; 94 percent",
"     </li>",
"     <li>",
"      51 to 60 years old &mdash; 87 percent",
"     </li>",
"     <li>",
"      61 to 70 years old &mdash; 78 percent",
"     </li>",
"     <li>",
"      71 to 80 years old &mdash; 71 percent",
"     </li>",
"     <li>",
"      &ge;80 years old &mdash; 54 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether age represents an independent prognostic factor is controversial. Women over the age of 65 have more frequent deep myometrial invasion, high tumor grade, and advanced tumor stage [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/7,12-15\">",
"     7,12-15",
"    </a>",
"    ]. Furthermore, less aggressive therapy could also account for some of the poor outcomes seen in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/12,14,15\">",
"     12,14,15",
"    </a>",
"    ]. As noted above, age is used to categorize women with intermediate-risk disease into either a high- or low- intermediate risk group, which may influence treatment decisions. (See",
"    <a class=\"local\" href=\"#H215731639\">",
"     'Intermediate-risk'",
"    </a>",
"    above.) However, even when treated in uniform fashion, older women seem to have higher recurrence rates and inferior survival compared to their younger counterparts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215731963\">",
"    <span class=\"h3\">",
"     Influence of race",
"    </span>",
"    &nbsp;&mdash;&nbsp;Race also factors into prognosis. Black women have a consistently poorer outcome than Caucasians, an effect that is incompletely explained by imbalances in psychosocial, clinicopathologic, and treatment factors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. Some of the racial disparity in survival has been attributed to a lower incidence of good prognosis (low-grade endometrioid) cancers in blacks and a higher incidence of high-risk (grade 3 and non-endometrioid) tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. However, an alternative explanation for the worse survival is provided by emerging data suggesting that at least in uterine serous cancers, blacks have a higher frequency of overexpressed or amplified HER2 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Asian women appear to have a better survival relative to other populations, an effect that is attributed at least in part to younger age at diagnosis. In data from the SEER of the National Cancer Institute, 1 in 50 Asian women with uterine cancer was diagnosed before age 35 as compared to 1 in 150 white women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1596994195\">",
"    <span class=\"h3\">",
"     Molecular prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of molecular factors hold promise for determining the prognostic value of routine surgical and histologic characteristics. These include p53 and p16 overexpression, PTEN mutations, markers of proliferation, microsatellite instability, or tumor expression of estrogen (ER)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progesterone (PR) receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/28-39\">",
"     28-39",
"    </a>",
"    ]. Until more data become available, however, they remain investigational and should not be incorporated into clinical decision making.",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 134 women who underwent complete surgical staging, p53 overexpression and high S phase fraction (&ge;9 percent) in preoperative endometrial curettage specimens were independent significant presurgical molecular determinants of outcome. The presence of both factors increased the risk of recurrence sevenfold, and the risk of cancer-related death almost 10-fold when compared with women with neither factor [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The absence of PR expression has been correlated with the presence of lymph node metastases and inferior survival in some reports [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. Absence of ER expression appears to have some prognostic value, but less than PR expression [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Many series report a more favorable outcome for women whose endometrial cancers arise in the setting of Lynch syndrome (hereditary nonpolyposis colorectal cancer, HNPCC), but there may be subsets with a poorer prognosis. Within the subgroup of endometrioid endometrial tumors with high-level microsatellite instability (MSI-H), tumors that harbor mutations in the cell cycle checkpoint gene ATR have a significantly worse prognosis than those with a wild-type ATR gene [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=see_link\">",
"       \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215732630\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215732927\">",
"    <span class=\"h2\">",
"     Fertility preservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with low-risk endometrial carcinoma who wish to preserve future fertility are candidates for conservative treatment using progestin therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    ). Women with higher risk disease are not candidates for progestin therapy and it is not an appropriate alternative to surgical treatment. A discussion of this option is covered in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=see_link\">",
"     \"Treatment of low-risk endometrial cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215732934\">",
"    <span class=\"h2\">",
"     Inoperable patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For inoperable patients, primary treatment with radiation or chemotherapy (based on risk) may be reasonable, although the impact of nonsurgical treatment on disease outcomes is not clear. As an example, a case control study failed to demonstrate that patients treated with primary radiation therapy had significantly lower survival compared to matched patients who underwent surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8855/abstract/40\">",
"     40",
"    </a>",
"    ]. Over one-third of deaths in this series were due to intercurrent illness, not recurrent cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link&amp;anchor=H22#H22\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\", section on 'Inoperable patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=see_link\">",
"       \"Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/12/8388?source=see_link\">",
"       \"Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1596994394\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of endometrial cancer following surgical staging depends on the risk of relapse and persistent disease. The risk is established based on stage and presence of prognostic factors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with low-risk endometrial carcinoma who wish to preserve future fertility are candidates for conservative treatment using progestin therapy. Women with higher risk disease are not candidates for progestin therapy and it is not an appropriate alternative to surgical treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=see_link\">",
"       \"Treatment of low-risk endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women with low grade (grade 1 or 2) endometrioid cancers confined to the endometrium (a subset of stage IA disease) are classified as having low-risk endometrial cancer. Because their prognosis following surgery is excellent, no adjuvant treatment is required. (See",
"      <a class=\"local\" href=\"#H1596994160\">",
"       'Risk stratification and overview of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with endometrial cancer that invades the myometrium (stage IA or IB) or demonstrate occult cervical stromal invasion (stage II) have intermediate-risk disease. Other adverse prognostic factors are used to stratify women in to high- or low-intermediate-risk endometrial cancer: outer one-third myometrial invasion, grade 2 or 3 differentiation, or the presence of lymphovascular invasion within the cancer. Women with intermediate risk disease are candidates for adjuvant radiation therapy (RT). Although there is no clear role for chemotherapy as part of an adjuvant treatment strategy, some clinicians recommend chemotherapy to women with high intermediate-risk disease. (See",
"      <a class=\"local\" href=\"#H215731639\">",
"       'Intermediate-risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who have any of the following features have high-risk endometrial cancer: stage III disease, regardless of histology or grade;",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      uterine serous carcinoma (USC) or clear cell carcinoma (CC) of any stage. Women with high-risk disease often receive chemotherapy with or without RT given their high risk of both distant and locoregional relapse. (See",
"      <a class=\"local\" href=\"#H1596994188\">",
"       'High-risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who refuse surgery or in whom surgery is not an option, we suggest pelvic radiation as primary treatment. (See",
"      <a class=\"local\" href=\"#H215732934\">",
"       'Inoperable patients'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/1\">",
"      Shah C, Johnson EB, Everett E, et al. Does size matter? Tumor size and morphology as predictors of nodal status and recurrence in endometrial cancer. Gynecol Oncol 2005; 99:564.",
"     </a>",
"    </li>",
"    <li>",
"     Corpus Uteri. In: American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.403.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/3\">",
"      Wethington SL, Barrena Medel NI, Wright JD, Herzog TJ. Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery. Gynecol Oncol 2009; 115:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/4\">",
"      Garg G, Gao F, Wright JD, et al. Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. Gynecol Oncol 2013; 128:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/5\">",
"      Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/6\">",
"      Abu-Rustum NR, Zhou Q, Gomez JD, et al. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol 2010; 116:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/7\">",
"      Jolly S, Vargas CE, Kumar T, et al. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. Gynecol Oncol 2006; 103:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/8\">",
"      Alektiar KM, Venkatraman E, Abu-Rustum N, Barakat RR. Is endometrial carcinoma intrinsically more aggressive in elderly patients? Cancer 2003; 98:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/9\">",
"      Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000; 355:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/10\">",
"      Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/11\">",
"      Lee NK, Cheung MK, Shin JY, et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol 2007; 109:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/12\">",
"      Mundt AJ, Waggoner S, Yamada D, et al. Age as a prognostic factor for recurrence in patients with endometrial carcinoma. Gynecol Oncol 2000; 79:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/13\">",
"      Grigsby PW, Perez CA, Kuten A, et al. Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system. Int J Radiat Oncol Biol Phys 1992; 22:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/14\">",
"      Goodwin JS, Samet JM, Key CR, et al. Stage at diagnosis of cancer varies with the age of the patient. J Am Geriatr Soc 1986; 34:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/15\">",
"      Samet J, Hunt WC, Key C, et al. Choice of cancer therapy varies with age of patient. JAMA 1986; 255:3385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/16\">",
"      Abu-Rustum NR, Alektiar K, Iasonos A, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 2006; 103:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/17\">",
"      Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994; 10:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/18\">",
"      Hicks ML, Phillips JL, Parham G, et al. The National Cancer Data Base report on endometrial carcinoma in African-American women. Cancer 1998; 83:2629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/19\">",
"      Connell PP, Rotmensch J, Waggoner SE, Mundt AJ. Race and clinical outcome in endometrial carcinoma. Obstet Gynecol 1999; 94:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/20\">",
"      Maxwell GL, Tian C, Risinger J, et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer 2006; 107:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/21\">",
"      Clifford SL, Kaminetsky CP, Cirisano FD, et al. Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. Am J Obstet Gynecol 1997; 176:S229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/22\">",
"      Farley JH, Tian C, Rose GS, et al. Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study. Cancer 2010; 116:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/23\">",
"      Plaxe SC, Saltzstein SL. Impact of ethnicity on the incidence of high-risk endometrial carcinoma. Gynecol Oncol 1997; 65:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/24\">",
"      Schimp VL, Ali-Fehmi R, Solomon LA, et al. The racial disparity in outcomes in endometrial cancer: could this be explained on a molecular level? Gynecol Oncol 2006; 102:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/25\">",
"      Berchuck A, Rodriguez G, Kinney RB, et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991; 164:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/26\">",
"      Hetzel DJ, Wilson TO, Keeney GL, et al. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992; 47:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/27\">",
"      Zhang MM, Cheung MK, Osann K, et al. Improved survival of Asians with corpus cancer compared with whites: an analysis of underlying factors. Obstet Gynecol 2006; 107:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/28\">",
"      Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2007; 106:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/29\">",
"      Silverman MB, Roche PC, Kho RM, et al. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. Gynecol Oncol 2000; 77:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/30\">",
"      Salvesen HB, Das S, Akslen LA. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 2000; 6:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/31\">",
"      Iwai K, Fukuda K, Hachisuga T, et al. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma. Gynecol Oncol 1999; 72:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/32\">",
"      Fukuda K, Mori M, Uchiyama M, et al. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 1998; 69:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/33\">",
"      Gehrig PA, Van Le L, Olatidoye B, Geradts J. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer 1999; 86:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/34\">",
"      Larson DM, Berg R, Shaw G, Krawisz BR. Prognostic significance of DNA ploidy in endometrial cancer. Gynecol Oncol 1999; 74:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/35\">",
"      Minaguchi T, Yoshikawa H, Oda K, et al. PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res 2001; 7:2636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/36\">",
"      Salvesen HB, Stefansson I, Kalvenes MB, et al. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer 2002; 94:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/37\">",
"      Black D, Soslow RA, Levine DA, et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol 2006; 24:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/38\">",
"      Zighelboim I, Goodfellow PJ, Gao F, et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol 2007; 25:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/39\">",
"      Zighelboim I, Schmidt AP, Gao F, et al. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. J Clin Oncol 2009; 27:3091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8855/abstract/40\">",
"      Rose PG, Baker S, Kern M, et al. Primary radiation therapy for endometrial carcinoma: a case controlled study. Int J Radiat Oncol Biol Phys 1993; 27:585.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16742 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8855=[""].join("\n");
var outline_f8_41_8855=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1596994394\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1596994125\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1596994160\">",
"      RISK STRATIFICATION AND OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1596994167\">",
"      Low-risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H215731639\">",
"      Intermediate-risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1596994188\">",
"      High-risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H215731739\">",
"      Other factors that affect risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H215731542\">",
"      - Lower uterine segment involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H215731098\">",
"      - Positive peritoneal cytology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H215731105\">",
"      - Influence of age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H215731963\">",
"      - Influence of race",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1596994195\">",
"      - Molecular prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H215732630\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H215732927\">",
"      Fertility preservation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H215732934\">",
"      Inoperable patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1596994394\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16742\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16742|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/33/43549\" title=\"table 1\">",
"      Staging uterine carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41991?source=related_link\">",
"      Adjuvant treatment of high-risk endometrial cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13287?source=related_link\">",
"      Adjuvant treatment of intermediate-risk endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=related_link\">",
"      Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=related_link\">",
"      Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/12/8388?source=related_link\">",
"      Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=related_link\">",
"      Treatment of low-risk endometrial cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_41_8856="Brain MRI of CLIPPERS";
var content_f8_41_8856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F85858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F85858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Brain MRI of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 590px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Initial T1-weighted postgadolinium brain MRI of a 48 year-old man with progressive vertigo, ataxia, and dysarthria.",
"    <br>",
"     A) Symmetric enhancement of the pons and both cerebellar peduncles, with pattern highly suggestive of a perivascular distribution.",
"     <br>",
"      B) Near complete resolution with corticosteroids.",
"      <br>",
"       C) Recurrence of the same lesions without corticosteroids.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Lefaucheur R, Bouwyn JP, Ahtoy P, G&eacute;rardin E, Derrey S, Malt&ecirc;te D. Teaching neuroimages: punctuate and curvilinear enhancement peppering the pons responsive to steroids. Neurology 2011; 77:e57. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8856=[""].join("\n");
var outline_f8_41_8856=null;
var title_f8_41_8857="Treatment of gonadotroph and other clinically nonfunctioning adenomas";
var content_f8_41_8857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of gonadotroph and other clinically nonfunctioning adenomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/41/8857/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/41/8857/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/41/8857/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/41/8857/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/41/8857/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/41/8857/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/41/8857/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadotroph adenomas are the most common pituitary macroadenomas, comprising about 80 percent of clinically nonfunctioning adenomas. These adenomas are difficult to identify because their secretory products usually do not cause a recognizable clinical syndrome and because they often secrete so inefficiently that serum concentrations of intact gonadotropins and their subunits are often only minimally abnormal or not abnormal at all. Consequently, they are typically not detected until they become sufficiently large to cause neurologic symptoms, most often impaired vision due to pressure on the optic chiasm. There are also rare cases of clinically nonfunctioning or &ldquo;silent&rdquo; somatotroph, lactotroph, and corticotroph adenomas.",
"   </p>",
"   <p>",
"    The treatment of gonadotroph and other clinically nonfunctioning adenomas will be reviewed here. Their clinical manifestations and diagnosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22489?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525038806\">",
"    <span class=\"h1\">",
"     MANAGEMENT APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213381710\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadotroph or other nonfunctioning macroadenomas are typically diagnosed when they become large enough to cause neurologic symptoms (eg, headaches, visual loss), a hormonal deficiency state, when an imaging study is performed for unrelated reasons, or less commonly, because of hormonal hypersecretion.",
"   </p>",
"   <p>",
"    Once identified, treatment should be promptly instituted for those with impaired vision, and considered for those at high risk for loss of vision (marked suprasellar tumor extension). Standard first-line therapy is transsphenoidal surgery, followed by radiation therapy if there is considerable residual adenomatous tissue. Long-term monitoring is necessary because the risk of tumor regrowth is significant, particularly after surgery alone. Radiation therapy is also indicated for patients whose adenoma recurs. Life-long management of pituitary hormone deficiencies is required in many patients. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Adjuvant radiation therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1213383709\">",
"     'Hormonal abnormalities'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525038814\">",
"    <span class=\"h2\">",
"     Goals of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment in patients with gonadotroph or nonfunctioning adenomas include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relief of visual impairment or other neurologic symptoms",
"     </li>",
"     <li>",
"      Removal of pituitary macroadenoma (as complete as possible to avoid recurrence)",
"     </li>",
"     <li>",
"      Management of hormonal deficiencies due to compression of nonadenomatous pituitary cells by the macroadenoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Surgical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transsphenoidal surgery is the treatment of choice for initial therapy, as it is currently the only treatment that can provide rapid relief of neurologic symptoms in patients with a gonadotroph or nonfunctioning adenoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Transsphenoidal surgery reduces the size of the adenoma and its hormonal hypersecretion in more than 90 percent of cases; it improves vision in about 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transcranial surgery is virtually never the preferred approach for the initial operation but might be considered when a large amount of residual adenoma is left in a suprasellar location.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525038276\">",
"    <span class=\"h3\">",
"     Preoperative preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important aspects of the preoperative preparation for pituitary surgery include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confirming the sellar lesion is a gonadotroph or other nonfunctioning adenoma, which must be distinguished from a nonpituitary lesion in or near the sella, which might best be approached transcranially. Abnormalities that strongly suggest a gonadotroph adenoma are elevated basal serum concentrations of intact FSH and of alpha subunit and a response of either to exogenous TRH, which is available only outside the United States. Approximately 20 percent of gonadotroph adenomas will exhibit one or more of these abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22489?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Identifying one of these biochemical markers can also be used to monitor the response to surgery and subsequent therapy.",
"     </li>",
"     <li>",
"      Identifying a highly experienced pituitary surgeon.",
"     </li>",
"     <li>",
"      Identifying any pituitary hormone deficiencies that need to be treated preoperatively, including hypothyroidism due to TSH deficiency, and hypocortisolism due to ACTH deficiency. Hypothyroidism, which increases the risk of respiratory insufficiency following postoperative administration of opiates or barbiturates, should be corrected preoperatively or pain medication should be used in lower than usual doses. Hypocortisolism should be replaced physiologically.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213382095\">",
"    <span class=\"h3\">",
"     Choice of procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the 1970s, transsphenoidal surgery has been performed to excise pituitary adenomas. The initial procedure employed a sublabial transeptal approach and an operating microscope. More recently, an endonasal endoscopic approach has been introduced and is being used increasingly. Its main advantage is better visualization of the operative site [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2559547\">",
"    <span class=\"h3\">",
"     Perioperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;An MRI on postoperative day 1 gives an initial view of how much of the adenoma has been removed, even though a more accurate view is provided when the artefacts of surgery have regressed three to six months later. Perioperative hormonal management should be directed toward abnormalities of cortisol and vasopressin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2559555\">",
"    <span class=\"h4\">",
"     Hypocortisolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the possibility that nonadenomatous pituitary tissue could be removed inadvertently when attempting to remove the large volume of adenoma, patients should be treated with 100 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    beginning at the induction of anesthesia. The dose should be gradually decreased during the next few days. We recommend a replacement dose (eg, 15 to 25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    following discharge until the initial postoperative evaluation four to six weeks after discharge. Others recommend measuring serum cortisol on the third postoperative day, 24 hours after the previous dose of hydrocortisone, and if the value is low (less than 4",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [110",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    or borderline (5 to 17",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [138 to 469",
"    <span class=\"nowrap\">",
"     nmol/L]),",
"    </span>",
"    prescribing replacement hydrocortisone on discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2559562\">",
"    <span class=\"h4\">",
"     Diabetes insipidus and SIADH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both diabetes insipidus and SIADH can occur shortly after transsphenoidal surgery.",
"   </p>",
"   <p>",
"    Diabetes insipidus is more common, occurring in 18.5 percent of one series of 319 patients who underwent pituitary surgery at one institution [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/7\">",
"     7",
"    </a>",
"    ] and 54.2 percent of 57 patients at another [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/8\">",
"     8",
"    </a>",
"    ]. It usually occurs within the first 24 hours postoperatively and is usually transient but is sometimes permanent. In the series of 319 patients, almost 50 percent had remitted in one week and about 80 percent in three months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SIADH is less common, occurring in 8.8 percent and 36.7 percent in the above two series [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In a third series, in which sodium was measured routinely on postoperative day 7 in 241 patients, 23 percent had asymptomatic hyponatremia and 5 percent symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/9\">",
"     9",
"    </a>",
"    ]. The mean serum sodium was 128.4",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    in the asymptomatic patients and 120.5",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    in the symptomatic ones. SIADH occurs between day 4 and day 10.",
"   </p>",
"   <p>",
"    Sometimes a patient experiences only diabetes insipidus, but less often the patient experiences diabetes insipidus followed by SIADH and, even less often, the SIADH is followed once more by diabetes insipidus [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possibility of these abnormalities in vasopressin secretion dictate that any patient who has transsphenoidal surgery be assessed daily postoperatively by inquiring about thirst and measuring fluid intake and output, serum sodium, and urine specific gravity. If diabetes insipidus has not occurred by the time of discharge, the serum sodium should be repeated as an outpatient on day 7.",
"   </p>",
"   <p>",
"    Diabetes insipidus that occurs in the first day after surgery, when absorption through the nasal mucosa is variable, should be treated with dDAVP intravenously in doses from 0.25 to 1.0 mcg every 12 to 24 hours, titrated to keep urine volume and serum sodium normal. If diabetes insipidus has not remitted by the time of discharge, the dDAVP can be given as a nasal spray. When the condition appears to be permanent, the nasal spray can be continued. If the condition is partial or the patient is very sensitive to dDAVP, it can be administered orally, 0.1 to 0.2 mg at bedtime alone or more often.",
"   </p>",
"   <p>",
"    SIADH is treated by fluid restriction until it remits, usually by postoperative day 10.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244024067\">",
"    <span class=\"h3\">",
"     Short-term monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four to six weeks after discharge from the hospital, the patient should be evaluated for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amount of residual adenoma. A crude estimation of the amount of residual adenoma can be determined by magnetic resonance imaging, but artifacts of surgery may obscure the actual amount of residual adenoma tissue for several months. A more accurate estimate of the amount of residual adenoma at this time can be attained by monitoring the serum concentration of any gonadotroph adenoma product, such as FSH or the free alpha subunit, that had been elevated before surgery.",
"     </li>",
"     <li>",
"      Visual function (by acuity and visual fields).",
"     </li>",
"     <li>",
"      Hormonal function of the nonadenomatous pituitary, regardless of whether it was normal or abnormal prior to surgery. This evaluation should include measurements of:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serum thyroxine.",
"     </li>",
"     <li>",
"      Early morning serum cortisol 24 hours after the previous dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      . If the serum cortisol value is &le;3",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (83",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      the patient has secondary adrenal insufficiency (ACTH deficiency); if it is &ge;18",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (497",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      the patient has normal adrenal function; if it is between 4 and 17",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (110 and 469",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      on three occasions, a test of corticotropin (ACTH) reserve, such as a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      test, should be performed. Metyrapone (Metopirone&reg;) is currently available in the US through its new manufacturer, HRA Pharma, and order forms can be obtained on their",
"      <a class=\"external\" href=\"file://www.metopirone.us/\">",
"       website",
"      </a>",
"      and faxed at 1-855-674-6767. Measurement of serum cortisol one hour after the administration of 250 mcg of cosyntropin should not be used in these patients because it may give a falsely normal result [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=see_link&amp;anchor=H9#H9\">",
"       \"Diagnosis of adrenal insufficiency in adults\", section on 'Establishing the level of defect'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum testosterone in a man or serum estradiol in a premenopausal woman.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      24-hour urine volume if the patient has significant nocturia. A water deprivation test should be performed if the urine output is above 3",
"      <span class=\"nowrap\">",
"       L/day;",
"      </span>",
"      values above 6",
"      <span class=\"nowrap\">",
"       L/day",
"      </span>",
"      are almost always due to diabetes insipidus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"       \"Diagnosis of polyuria and diabetes insipidus\"",
"      </a>",
"      .) Any hormonal deficiencies that are identified should be treated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28006?source=see_link\">",
"       \"Treatment of hypopituitarism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213382924\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transsphenoidal surgery reduces the size of the adenoma in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244023969\">",
"    <span class=\"h4\">",
"     Residual adenoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although results are widely variable by center and surgeon, in a meta-analysis of 58 case series of patients with nonfunctioning pituitary adenomas undergoing transsphenoidal surgery, complete removal of the adenoma, as judged by the surgeon, was achieved in only 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/11\">",
"     11",
"    </a>",
"    ]. More experienced surgeons and high volume centers have higher rates of complete removal (approximately 65 to 75 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/4,12\">",
"     4,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 20 percent of adenomas recur after transsphenoidal surgery alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/11\">",
"     11",
"    </a>",
"    ]; however, the risk of recurrence is much lower if there is no MRI evidence of residual adenoma after surgery. In addition, if there is evidence of residual adenoma, the addition of radiation therapy lowers the risk of subsequent recurrence (see",
"    <a class=\"local\" href=\"#H1213383547\">",
"     'Adenoma regrowth'",
"    </a>",
"    below). Radiation therapy is typically started if an MRI performed 6 to 12 months after surgery shows substantial residual adenoma tissue or if residual adenoma tissue shows progressive growth in the months or years after surgery. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Adjuvant radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213383702\">",
"    <span class=\"h4\">",
"     Visual function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transsphenoidal surgery improves visual function in approximately 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/3\">",
"     3",
"    </a>",
"    ]; improvement can be seen in the first few days after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. If visual function was abnormal before surgery, it should be reevaluated a month or two afterward and less often until no further change occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213383709\">",
"    <span class=\"h4\">",
"     Hormonal abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the improvement in vision that is seen, improvement in pituitary function is less likely. Preoperatively, the majority of patients have pituitary hormone deficiencies, most commonly, growth hormone deficiency. In the meta-analysis described above, in patients with preoperative pituitary hormone abnormalities, 30 percent of patients experienced an improvement in some hormone deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/11\">",
"     11",
"    </a>",
"    ]. However, most patients are left with long-term deficiencies that need replacement. In a systematic review of eight studies in over 1000 patients, the approximate frequencies of postoperative hormone deficiencies were [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth hormone &ndash; 83 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       LH/FSH",
"      </span>",
"      &ndash; 60 percent",
"     </li>",
"     <li>",
"      TSH &ndash; 30 percent",
"     </li>",
"     <li>",
"      ACTH &ndash; 30 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213381995\">",
"    <span class=\"h4\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the meta-analysis described above, the mortality rate in the immediate postoperative period was 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/11\">",
"     11",
"    </a>",
"    ]. Serious complications occurred in less than 5 percent of patients, and included cerebrospinal fluid leakage, fistula, meningitis, and new visual field defects.",
"   </p>",
"   <p>",
"    The risk of complications is inversely proportional to the experience of the surgeon in performing transsphenoidal surgery. In one study, 958 neurosurgeons reported their own experiences in response to a questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/1\">",
"     1",
"    </a>",
"    ]. Both serious complications, such as loss of vision and death, and less serious complications, such as hormonal deficiencies, were higher among surgeons who had performed fewer transsphenoidal procedures (",
"    <a class=\"graphic graphic_table graphicRef68269 \" href=\"UTD.htm?27/24/28044\">",
"     table 1",
"    </a>",
"    ). For example, among neurosurgeons who reported performing fewer than 200 transsphenoidal procedures, 1.2 percent of procedures resulted in death, but among neurosurgeons who reported performing more than 500 procedures, only 0.2 percent resulted in death. A second study utilized a national database and found that among 825 surgeons who performed 5497 operations, the complication rate was also less among surgeons who performed more transsphenoidal procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adjuvant radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy is useful in preventing regrowth of residual adenoma tissue following transsphenoidal surgery. The decision as to whether or not radiation should be administered is based on the amount and location of the residual tissue, an assessment of the aggressiveness of the adenoma, and the patient&rsquo;s age and general health status. If the postop day 1 MRI shows a large amount of residual adenoma tissue, the decision to radiate could be made a month after surgery, but otherwise the decision is usually made by an MRI performed three to six months after surgery, when artefacts of surgery have regressed.",
"   </p>",
"   <p>",
"    Radiation is also useful when there is evidence of adenoma regrowth in the months or years after surgery. When administered for adenoma regrowth, conventional radiation therapy results in 10 year control rates, defined as lack of progression clinically and radiologically, of approximately 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    Radiation therapy is usually not employed as primary therapy for gonadotroph and other clinically nonfunctioning pituitary adenomas because its effects occur too slowly to be appropriate when a patient has visual impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     \"Conventional\" radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This term refers to supervoltage radiation, administered in 23 to 25 daily doses of 2 Gy each, without stereotactic mapping. This is the type of radiation therapy that had been used commonly for many years, and much of the information available about long-term effects comes from studies of this treatment. This has been supplanted by stereotactic radiation, described below. Side effects of conventional radiation therapy can occur both during therapy and up to 10 years later. Side effects of stereotactic radiation appear similar.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms that occurred during treatment include nausea, lethargy, loss of taste and smell, and loss of hair at the radiation portals. The first two remit within one to two months, and the last two usually remit within six months.",
"     </li>",
"     <li>",
"      The most common late complication was hypopituitarism [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/20\">",
"       20",
"      </a>",
"      ]. There was an approximately 50 percent likelihood that at least one pituitary hormone that was normal prior to radiation became subnormal within the ensuing five years [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neurologic complications were less common but more serious. Optic neuropathy has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/18,22\">",
"       18,22",
"      </a>",
"      ], as well as second, malignant brain tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]. Anecdotes also suggest increased risk of cerebrovascular disease, but there is little documentation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Stereotactic radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of radiation stereotactically has superseded the conventional approach in many centers, based upon the rationale that directing the radiation more precisely to the adenoma will spare surrounding structures and thereby reduce the incidence of neurologic complications. The stereotactic approach can be used no matter the source of the radiation or if it is given as a fractionated dose or a single dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several series have now reported the results of fractionated radiotherapy using a linear accelerator [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/26-30\">",
"     26-30",
"    </a>",
"    ] or proton beam [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/31\">",
"     31",
"    </a>",
"    ] in patients with pituitary adenomas for a median duration of observation of 36 months or more. The following results were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenoma size was reduced or stable in 90 to 100 percent of the patients.",
"     </li>",
"     <li>",
"      No neurologic damage attributable to the radiation was observed in the two studies in which radiation was delivered by linear accelerator [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/29,30\">",
"       29,30",
"      </a>",
"      ], but in another report of 68 patients, radiation-induced ophthalmopathy occurred in two patients [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/26\">",
"       26",
"      </a>",
"      ]. In the study of proton beam treatment, temporal lobe necrosis occurred in one patient and new visual deficiencies in three [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pituitary hormonal deficiencies developed in approximately one-third of the subjects in the three studies during the median observation period of 40 or more months [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/29-32\">",
"       29-32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results seem relatively good, but no better or worse than conventional radiation therapy.",
"   </p>",
"   <p>",
"    The occurrence of two cases of optic neuropathy is troubling; however, it suggests that the goal of reducing neurologic complications by this stereotactic approach may not be realized.",
"   </p>",
"   <p>",
"    Two reports describe the results of single-dose radiation in patients with pituitary adenomas. One report is a review of 35 studies that involved 1621 patients (452 with clinically nonfunctioning adenomas) treated with single-dose radiation from a linear accelerator, gamma source, or proton beam, in which the median period of observation was &lt;40 months in about half and &gt;40 months in about half [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/33\">",
"     33",
"    </a>",
"    ]. In the entire group of patients, adenoma size was controlled in approximately 90 percent; development of new hypopituitarism varied widely among individual reports; optic neuropathy occurred in about 1 percent; other cranial neuropathies occurred in about 1.3 percent; and parenchymal brain damage, especially in the hypothalamus and temporal lobe, occurred in about 0.8 percent.",
"   </p>",
"   <p>",
"    In a subsequent report from a single center, 100 patients with clinically nonfunctioning adenomas were treated with single-dose radiation from a gamma source and followed for a median of 45 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/34\">",
"     34",
"    </a>",
"    ]. Adenoma volume decreased or remained stable in about 92 percent, and new hypopituitarism developed in about 20 percent overall and 25 percent in those followed for less than two years. No new neurological deficits occurred.",
"   </p>",
"   <p>",
"    Overall, single-dose radiation also appears to give good results, but not clearly superior to those previously reported with conventional radiation.",
"   </p>",
"   <p>",
"    Stereotactic radiotherapy has also been utilized for other pituitary tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=see_link\">",
"     \"Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Unproven therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extraordinary success of dopamine agonists in reducing the size of, as well as secretion by, lactotroph adenomas has prompted attempts to find a pharmacologic treatment for gonadotroph adenomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"    </a>",
"    .) To date, however,",
"    <strong>",
"     no drug",
"    </strong>",
"    has been found that consistently and substantially reduces the size of gonadotroph adenomas.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     Bromocriptine",
"    </a>",
"    therapy for nonfunctioning adenomas has been disappointing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/3\">",
"     3",
"    </a>",
"    ];",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    may have some effect [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/35\">",
"     35",
"    </a>",
"    ]. However, data are limited and this drug would not be considered to be an alternative for surgery. The cell membranes of some clinically nonfunctioning pituitary adenomas have somatostatin receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Two groups have administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (a somatostatin analogue) to such patients. One found improvement in visual fields in three of four patients, but no decrease in adenoma size [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/38\">",
"     38",
"    </a>",
"    ]. The other found decreases in serum alpha subunit values in three of six patients and a reduction in tumor size and visual impairment in two each; there was, however, no correlation among the three measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Administration of a GnRH antagonist is the most effective approach tested thus far in suppressing FSH secretion by gonadotroph adenomas. In one report, for example, administration of Nal-Glu GnRH for one week to men with gonadotroph adenomas normalized their high serum FSH concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/40\">",
"     40",
"    </a>",
"    ]. In another study, serum FSH concentrations remained low for the entire six-month treatment period; however, adenoma size did not decrease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/41\">",
"     41",
"    </a>",
"    ]. These results suggest that FSH secretion by gonadotroph adenomas, but not adenoma size, is dependent upon endogenous GnRH.",
"   </p>",
"   <p>",
"    The rationale for the use of gonadotropin-releasing hormone agonists in patients with gonadotroph adenomas is that chronic administration causes down-regulation of GnRH receptors on and decreased secretion of gonadotropins from normal gonadotroph cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=see_link\">",
"     \"Physiology of gonadotropin-releasing hormone\"",
"    </a>",
"    .) Unfortunately, administration of GnRH agonist analogs to patients with gonadotroph adenomas usually has either an agonist effect or no change in gonadotropin secretion and does not affect adenoma size [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213383540\">",
"    <span class=\"h2\">",
"     Long-term follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term monitoring should include testing every 6 to 12 months initially to detect growth of residual adenoma tissue and the adequacy of hormonal replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213383547\">",
"    <span class=\"h3\">",
"     Adenoma regrowth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of regrowth of residual adenoma tissue varies but is more likely when surgery is not combined with radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/11\">",
"     11",
"    </a>",
"    ]. In one report of 91 patients with nonfunctioning pituitary macroadenomas who underwent surgery without radiotherapy, tumor regrowth was seen in 10 percent of patients, with a mean time to tumor regrowth of approximately six years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/45\">",
"     45",
"    </a>",
"    ]. In contrast, two series of 491 and 159 patients had higher recurrence rates of 19 and 34 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/12,46\">",
"     12,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation for tumor regrowth should include measurement of whatever serum marker was elevated before surgery and an MRI; if there is no regrowth after a year or two, the interval between scans can be lengthened. Early detection permits appropriate use of radiation therapy to minimize the need for repeat surgery.",
"   </p>",
"   <p>",
"    Not surprisingly, patients who undergo subtotal resection of an adenoma with suprasellar extension are at high risk for recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. These patients benefit from adjuvant radiotherapy. However, radiotherapy is associated with long-term morbidity and should not be used routinely. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Adjuvant radiation therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If MRI six months after transsphenoidal surgery shows little adenoma tissue or the residual tissue is not in a location of clinical significance, we recommend observation only by MRI, initially yearly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213384753\">",
"    <span class=\"h3\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality of life (QOL) has been reported to be reduced after long-term cure of functioning pituitary adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Patients with nonfunctioning pituitary macroadenomas treated successfully by transsphenoidal surgery alone or combined with radiotherapy also have impaired quality of life when compared with age-matched, healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, patients commonly experience increased fatigue and daytime somnolence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/51\">",
"     51",
"    </a>",
"    ]. The impaired QOL and fatigue appear to be due to the underlying hypopituitarism that is present in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/49\">",
"     49",
"    </a>",
"    ], as well as impaired sleep quality and abnormal distribution of sleep stages [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7585601\">",
"    <span class=\"h1\">",
"     ASYMPTOMATIC ADENOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadotroph adenomas that are asymptomatic and not an immediate threat to vision may not require surgery, although hormonal deficiencies should be treated, and reevaluation of adenoma size and pituitary function should be performed at yearly intervals.",
"   </p>",
"   <p>",
"    This situation is increasingly common because an increasing number of gonadotroph or nonfunctioning adenomas are detected as incidental findings when MRI is performed for other reasons, such as head trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12981?source=see_link\">",
"     \"Incidentally discovered sellar masses (pituitary incidentalomas)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited data are available on the natural history of nonfunctioning macroadenomas because most patients undergo surgery. However, in studies that have monitored growth of these tumors for more than four to five years, approximately 50 percent of patients experienced adenoma growth [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/3,53-55\">",
"     3,53-55",
"    </a>",
"    ]. Thus, although watchful waiting may be appropriate in some cases, long-term follow-up is necessary as tumor growth can be anticipated in 50 percent of patients.",
"   </p>",
"   <p>",
"    In a small percent of cases, nonfunctioning adenomas may spontaneously regress. In a review of 10 series, this occurred in 34 of 304 patients (11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/3\">",
"     3",
"    </a>",
"    ], and was thought to be due to silent ischemia, while in an individual series of 37 patients with five years of follow-up, four experienced pituitary apoplexy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8857/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/28/7619?source=see_link\">",
"       \"Patient information: Pituitary adenoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with gonadotroph or other clinically non-functioning pituitary adenomas that are large enough to cause neurologic symptoms, such as visual field abnormalities, we recommend transsphenoidal surgery as initial therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The choice of surgical procedure, microscopic or endoscopic, depends upon the neurosurgeon&rsquo;s experience. (See",
"      <a class=\"local\" href=\"#H1213381710\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have extrasellar extension but do not have neurologic symptoms, we suggest discussing with the patient the risks of surgery versus the risks of waiting. For example, an adenoma that is markedly elevating the optic chiasm is very likely to begin to cause visual abnormalities in the next few years, yet some patients will choose to wait until that occurs. These patients should be followed by an MRI and visual field examinations every 6 to 12 months.",
"     </li>",
"     <li>",
"      If little or no residual adenoma tissue remains 6 to 12 months after surgery or if a larger amount remains but does not threaten neurologic complications, we suggest monitoring the residual tissue with MRI (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If the residual tissue grows progressively, we suggest radiation therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The type of radiation therapy depends upon what is available at a center with experience in radiation to the pituitary. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Adjuvant radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adenomas that are not causing visual symptoms, we suggest yearly monitoring of pituitary function and adenoma size (MRI). (See",
"      <a class=\"local\" href=\"#H7585601\">",
"       'Asymptomatic adenomas'",
"      </a>",
"      above.) Hormonal deficiencies should be replaced.",
"     </li>",
"     <li>",
"      Hormonal hypersecretion by the adenoma, when present, can be used to monitor the effects of treatment. (See",
"      <a class=\"local\" href=\"#H525038276\">",
"       'Preoperative preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hormonal deficiencies due to impaired function of the nonadenomatous pituitary should be replaced. Whatever treatment is used, lifetime re-evaluation is needed. (See",
"      <a class=\"local\" href=\"#H244024067\">",
"       'Short-term monitoring'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28006?source=see_link\">",
"       \"Treatment of hypopituitarism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/1\">",
"      Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997; 40:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/2\">",
"      Wilson CB. Surgical management of pituitary tumors. J Clin Endocrinol Metab 1997; 82:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/3\">",
"      Dekkers OM, Pereira AM, Romijn JA. Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab 2008; 93:3717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/4\">",
"      Messerer M, De Battista JC, Raverot G, et al. Evidence of improved surgical outcome following endoscopy for nonfunctioning pituitary adenoma removal. Neurosurg Focus 2011; 30:E11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/5\">",
"      Inder WJ, Hunt PJ. Glucocorticoid replacement in pituitary surgery: guidelines for perioperative assessment and management. J Clin Endocrinol Metab 2002; 87:2745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/6\">",
"      Ausiello JC, Bruce JN, Freda PU. Postoperative assessment of the patient after transsphenoidal pituitary surgery. Pituitary 2008; 11:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/7\">",
"      Adams JR, Blevins LS Jr, Allen GS, et al. Disorders of water metabolism following transsphenoidal pituitary surgery: a single institution's experience. Pituitary 2006; 9:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/8\">",
"      Kristof RA, Rother M, Neuloh G, Klingm&uuml;ller D. Incidence, clinical manifestations, and course of water and electrolyte metabolism disturbances following transsphenoidal pituitary adenoma surgery: a prospective observational study. J Neurosurg 2009; 111:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/9\">",
"      Zada G, Liu CY, Fishback D, et al. Recognition and management of delayed hyponatremia following transsphenoidal pituitary surgery. J Neurosurg 2007; 106:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/10\">",
"      Streeten DH, Anderson GH Jr, Bonaventura MM. The potential for serious consequences from misinterpreting normal responses to the rapid adrenocorticotropin test. J Clin Endocrinol Metab 1996; 81:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/11\">",
"      Murad MH, Fern&aacute;ndez-Balsells MM, Barwise A, et al. Outcomes of surgical treatment for nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2010; 73:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/12\">",
"      Losa M, Mortini P, Barzaghi R, et al. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 2008; 108:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/13\">",
"      Kerrison JB, Lynn MJ, Baer CA, et al. Stages of improvement in visual fields after pituitary tumor resection. Am J Ophthalmol 2000; 130:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/14\">",
"      Jakobsson KE, Petruson B, Lindblom B. Dynamics of visual improvement following chiasmal decompression. Quantitative pre- and postoperative observations. Acta Ophthalmol Scand 2002; 80:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/15\">",
"      Barker FG 2nd, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003; 88:4709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/16\">",
"      Woollons AC, Hunn MK, Rajapakse YR, et al. Non-functioning pituitary adenomas: indications for postoperative radiotherapy. Clin Endocrinol (Oxf) 2000; 53:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/17\">",
"      Tsang RW, Brierley JD, Panzarella T, et al. Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors. Int J Radiat Oncol Biol Phys 1994; 30:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/18\">",
"      McCord MW, Buatti JM, Fennell EM, et al. Radiotherapy for pituitary adenoma: long-term outcome and sequelae. Int J Radiat Oncol Biol Phys 1997; 39:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/19\">",
"      van den Bergh AC, van den Berg G, Schoorl MA, et al. Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys 2007; 67:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/20\">",
"      Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 2011; 96:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/21\">",
"      Snyder PJ, Fowble BF, Schatz NJ, et al. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med 1986; 81:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/22\">",
"      Zierhut D, Flentje M, Adolph J, et al. External radiotherapy of pituitary adenomas. Int J Radiat Oncol Biol Phys 1995; 33:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/23\">",
"      Brada M, Ford D, Ashley S, et al. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ 1992; 304:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/24\">",
"      Tsang RW, Laperriere NJ, Simpson WJ, et al. Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer 1993; 72:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/25\">",
"      Minniti G, Traish D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 2005; 90:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/26\">",
"      Paek SH, Downes MB, Bednarz G, et al. Integration of surgery with fractionated stereotactic radiotherapy for treatment of nonfunctioning pituitary macroadenomas. Int J Radiat Oncol Biol Phys 2005; 61:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/27\">",
"      Pollock BE, Cochran J, Natt N, et al. Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys 2008; 70:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/28\">",
"      Pamir MN, Kili&ccedil; T, Belirgen M, et al. Pituitary adenomas treated with gamma knife radiosurgery: volumetric analysis of 100 cases with minimum 3 year follow-up. Neurosurgery 2007; 61:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/29\">",
"      Colin P, Jovenin N, Delemer B, et al. Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a prospective study of 110 patients. Int J Radiat Oncol Biol Phys 2005; 62:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/30\">",
"      Mackley HB, Reddy CA, Lee SY, et al. Intensity-modulated radiotherapy for pituitary adenomas: the preliminary report of the Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007; 67:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/31\">",
"      Ronson BB, Schulte RW, Han KP, et al. Fractionated proton beam irradiation of pituitary adenomas. Int J Radiat Oncol Biol Phys 2006; 64:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/32\">",
"      Feigl GC, Bonelli CM, Berghold A, Mokry M. Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function. J Neurosurg 2002; 97:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/33\">",
"      Sheehan JP, Niranjan A, Sheehan JM, et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 2005; 102:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/34\">",
"      Mingione V, Yen CP, Vance ML, et al. Gamma surgery in the treatment of nonsecretory pituitary macroadenoma. J Neurosurg 2006; 104:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/35\">",
"      Greenman Y, Tordjman K, Osher E, et al. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocrinol (Oxf) 2005; 63:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/36\">",
"      Ikuyama S, Nawata H, Kato K, et al. Specific somatostatin receptors on human pituitary adenoma cell membranes. J Clin Endocrinol Metab 1985; 61:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/37\">",
"      Reubi JC, Heitz PU, Landolt AM. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses. J Clin Endocrinol Metab 1987; 65:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/38\">",
"      de Bruin TW, Kwekkeboom DJ, Van't Verlaat JW, et al. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab 1992; 75:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/39\">",
"      Katznelson L, Oppenheim DS, Coughlin JF, et al. Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors. J Clin Endocrinol Metab 1992; 75:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/40\">",
"      Daneshdoost L, Pavlou SN, Molitch ME, et al. Inhibition of follicle-stimulating hormone secretion from gonadotroph adenomas by repetitive administration of a gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 1990; 71:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/41\">",
"      McGrath GA, Goncalves RJ, Udupa JK, et al. New technique for quantitation of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 1993; 76:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/42\">",
"      Roman SH, Goldstein M, Kourides IA, et al. The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor. J Clin Endocrinol Metab 1984; 58:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/43\">",
"      Sassolas G, Lejeune H, Trouillas J, et al. Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1988; 67:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/44\">",
"      Klibanski A, Jameson JL, Biller BM, et al. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors. J Clin Endocrinol Metab 1989; 68:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/45\">",
"      Dekkers OM, Pereira AM, Roelfsema F, et al. Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2006; 91:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/46\">",
"      O'Sullivan EP, Woods C, Glynn N, et al. The natural history of surgically treated but radiotherapy-na&iuml;ve nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf) 2009; 71:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/47\">",
"      Chang EF, Zada G, Kim S, et al. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 2008; 108:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/48\">",
"      Biermasz NR, van Thiel SW, Pereira AM, et al. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 2004; 89:5369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/49\">",
"      van Aken MO, Pereira AM, Biermasz NR, et al. Quality of life in patients after long-term biochemical cure of Cushing's disease. J Clin Endocrinol Metab 2005; 90:3279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/50\">",
"      Dekkers OM, van der Klaauw AA, Pereira AM, et al. Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2006; 91:3364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/51\">",
"      van der Klaauw AA, Biermasz NR, Pereira AM, et al. Patients cured from craniopharyngioma or nonfunctioning pituitary macroadenoma (NFMA) suffer similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls. Clin Endocrinol (Oxf) 2008; 69:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/52\">",
"      Biermasz NR, Joustra SD, Donga E, et al. Patients previously treated for nonfunctioning pituitary macroadenomas have disturbed sleep characteristics, circadian movement rhythm, and subjective sleep quality. J Clin Endocrinol Metab 2011; 96:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/53\">",
"      Arita K, Tominaga A, Sugiyama K, et al. Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination. J Neurosurg 2006; 104:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/54\">",
"      Dekkers OM, Hammer S, de Keizer RJ, et al. The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol 2007; 156:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8857/abstract/55\">",
"      Karavitaki N, Collison K, Halliday J, et al. What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol (Oxf) 2007; 67:938.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6631 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-894C5EFDCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8857=[""].join("\n");
var outline_f8_41_8857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H525038806\">",
"      MANAGEMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1213381710\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525038814\">",
"      Goals of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Surgical approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H525038276\">",
"      - Preoperative preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1213382095\">",
"      - Choice of procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2559547\">",
"      - Perioperative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2559555\">",
"      Hypocortisolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2559562\">",
"      Diabetes insipidus and SIADH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H244024067\">",
"      - Short-term monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1213382924\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H244023969\">",
"      Residual adenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1213383702\">",
"      Visual function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1213383709\">",
"      Hormonal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1213381995\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adjuvant radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - \"Conventional\" radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Stereotactic radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Unproven therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1213383540\">",
"      Long-term follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1213383547\">",
"      - Adenoma regrowth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1213384753\">",
"      - Quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7585601\">",
"      ASYMPTOMATIC ADENOMAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/6631\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6631|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/24/28044\" title=\"table 1\">",
"      Complications of transsphenoidal surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22489?source=related_link\">",
"      Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12981?source=related_link\">",
"      Incidentally discovered sellar masses (pituitary incidentalomas)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/28/7619?source=related_link\">",
"      Patient information: Pituitary adenoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=related_link\">",
"      Physiology of gonadotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=related_link\">",
"      Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28006?source=related_link\">",
"      Treatment of hypopituitarism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_41_8858="Hyponatremia following transurethral resection or hysteroscopy";
var content_f8_41_8858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hyponatremia following transurethral resection or hysteroscopy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/41/8858/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/41/8858/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/41/8858/contributors\">",
"     Olav Istre, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/41/8858/contributors\">",
"     Robert G Hahn, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/41/8858/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/41/8858/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/41/8858/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/41/8858/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/41/8858/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/41/8858/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/41/8858/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of transurethral, hysteroscopic, and other percutaneous procedures utilize large volumes of",
"    <span class=\"nowrap\">",
"     irrigating/distension",
"    </span>",
"    solutions. These procedures include transurethral resection of the prostate (TURP), transurethral resection of bladder tumors, hysteroscopic transcervical diagnostic and therapeutic procedures (eg, resection of submucosal leiomyomas), percutaneous removal of kidney stones, and some other percutaneous and minimally invasive procedures.",
"   </p>",
"   <p>",
"    The electrosurgery devices that have traditionally been used during these procedures have a monopolar design and cannot be used with electrolyte-containing irrigation fluids (eg, isotonic saline or lactated Ringer's). Several different nonconductive (ie, non-electrolyte) solutions have been employed. The use of these non-electrolyte solutions has been associated with a number of complications including hyponatremia, a variable degree of hypoosmolality, and certain solution-specific problems described below.",
"   </p>",
"   <p>",
"    Bipolar electrosurgery devices and various laser and microwave systems have been introduced, and these devices are compatible with electrolyte-containing irrigation and distension solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Use of these solutions reduces the risk for development of hyponatremia. However, absorption of a large volume of saline solution will expand the extracellular fluid volume and may generate volume overload, pulmonary edema, and hypertension.",
"   </p>",
"   <p>",
"    Hyponatremia following use of nonconductive (ie, non-electrolyte) irrigation solutions for transurethral resection of the prostate or bladder or for hysteroscopy will be reviewed here. General principles of diagnosis and management of hyponatremia and of TUR and hysteroscopy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link\">",
"     \"Overview of the treatment of hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link\">",
"     \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link\">",
"     \"Overview of hysteroscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22951?source=see_link&amp;anchor=H4#H4\">",
"     \"Hysteroscopy: Managing fluid and gas distending media\", section on 'Fluid media'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONCONDUCTIVE IRRIGATION FLUIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three major nonconductive (ie, non-electrolyte) fluids are used for surgical procedures:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1.5 percent glycine (most commonly used)",
"     </li>",
"     <li>",
"      3 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"       sorbitol",
"      </a>",
"     </li>",
"     <li>",
"      5 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glycine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    solutions are hypoosmotic, having an osmolality of 200 and 165",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    respectively, compared to the normal serum osmolality of 280 to 296",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    In contrast, the 5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    solution is almost isosmotic to plasma (275",
"    <span class=\"nowrap\">",
"     mosmol/kg).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia following transurethral resection, hysteroscopy, or other percutaneous procedures using nonconductive (ie, non-electrolyte) irrigation solutions is an uncommon event. The severity of hyponatremia is directly related to the volume of irrigation fluid that is retained. Patients with a decrease in serum sodium of 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or more are likely to develop neurologic symptoms. The volume of irrigant fluid absorption required to develop this degree of hyponatremia is smaller in women than in men (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Volume and rate of fluid absorption'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Pathogenesis of neurologic symptoms'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Based upon data from large multicenter series, hyponatremia severe enough to produce confusion and nausea and vomiting (each of which can also be due to other factors) occurs in approximately 2 percent of men undergoing TUR of the prostate (this is often called the \"post-TURP syndrome\") [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/3,6\">",
"     3,6",
"    </a>",
"    ], while fluid overload",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyponatremia occurs in 0.06 to 0.2 percent of women undergoing hysteroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Hyponatremia also occurs after percutaneous nephrolithotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major risk factor for hyponatremia following transurethral resection, hysteroscopy, or other percutaneous procedures is the volume of irrigant absorbed. Absorption of 1000 mL of glycine irrigation fluid in women undergoing hysteroscopy is associated with a reduction in serum sodium of approximately 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef74942 \" href=\"UTD.htm?43/28/44494\">",
"     figure 1",
"    </a>",
"    ), while 3000 mL reduces the serum sodium by approximately 30",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Men undergoing TUR of the prostate show smaller reductions of 6 to 8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    after absorbing 1000 mL and 20",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    after absorbing 3000 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. These gender differences are probably due mostly to higher lean body weight and total body water in men. Thus, men must absorb more fluid than women to produce the same dilutional reduction in serum sodium (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Halt procedure at absorption thresholds'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Procedural risk factors for excess fluid absorption and hyponatremia during endoscopic procedures include the type of procedure (operative versus diagnostic), introduction of fluid at high pressure, visceral perforation, prolonged operative time, and type of anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Operative procedures are associated with a higher risk of excess fluid absorption than diagnostic procedures. When tissue is resected, veins may be severed (eg, large prostatic veins) or uterine venous sinuses may be exposed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. Irrigation fluid can then be directly and rapidly absorbed into the vascular system. In hysteroscopy, for example, the risk of excess fluid absorption is particularly high during resection of fibroids. The risk is much lower with diagnostic procedures, since monopolar electrosurgery is not performed and nonconductive (ie, non-electrolyte) fluids are not required.",
"   </p>",
"   <p>",
"    Fluid absorption into the vascular space begins when the fluid pressure exceeds the venous pressure (about 10 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/15\">",
"     15",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H13\">",
"     'Minimize fluid pressure'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In addition to fluid absorption directly into the vascular space (intravasation), perforation of a viscus during surgery can result in rapid extravasation of irrigation fluid into the surrounding space. With perforation of the bladder or uterine wall, fluid will extravasate into the peritoneal cavity or retroperitoneum. With perforation of the prostatic capsule during transurethral resection (TUR), fluid extravasates into the periprostatic space [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/12,15-17\">",
"     12,15-17",
"    </a>",
"    ]. Fluid can also traverse the Fallopian tubes during hysteroscopy; however, a history of prior tubal ligation does not seem to affect the volume of fluid absorbed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. The fall in serum sodium occurs more slowly following extravasation compared to intravasation (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Time course of hyponatremia'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Prolonged operative time permits greater opportunity for fluid absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. However, the available data are not sufficient to define an operative time threshold beyond which excessive fluid absorption is likely to occur. For TUR of the prostate, fluid absorption is greater during the second half of the procedure, regardless of operating time [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/21\">",
"     21",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H11\">",
"     'Monitor fluid absorbed'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The type of anesthesia may influence fluid absorption in women undergoing endometrial resection, although the available data are conflicting. In a randomized trial of 24 women undergoing hysteroscopy, fluid absorption was significantly higher with epidural compared to general anesthesia (648 versus 381 mL) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/22\">",
"     22",
"    </a>",
"    ]. In contrast, a subsequent retrospective cohort study found that fluid absorption was highest with general anesthesia, less with epidural anesthesia, and lowest with local anesthesia and intravenous sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The administration of intracervical vasopressin to reduce bleeding during hysteroscopy appears to protect against the development of hyponatremia by reducing local absorption of the irrigation fluid. In a randomized trial of 33 women undergoing hysteroscopic endometrial ablation, intracervical administration of vasopressin during hysteroscopy was associated with a significantly lower plasma glycine concentration at 20 minutes (8.8 versus 16.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and a nonsignificantly smaller reduction in plasma sodium from baseline (2.2 versus 6.8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at 40 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/24\">",
"     24",
"    </a>",
"    ]. Possible protection against hyponatremia was also noted in an observational study of intraprostatic administration of vasopressin in men undergoing TUR of the prostate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/25\">",
"     25",
"    </a>",
"    ]. In contrast to the possible benefits of intracervical or intraprostatic vasopressin, the systemic effects of vasopressin would be expected to exacerbate any reduction in serum sodium by limiting water excretion.",
"   </p>",
"   <p>",
"    There are limited data regarding patient-specific risk factors for excess fluid absorption and hyponatremia following TUR of the prostate or bladder or hysteroscopy. For men undergoing TUR of the prostate, smoking was associated with fluid absorption exceeding 1000 mL in a retrospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/26\">",
"     26",
"    </a>",
"    ]. The physiologic basis of such an effect, if real, might be that the blood supply to the prostate increases due to the variable degree of hypoxemia that accompanies smoking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF HYPONATREMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Volume and rate of fluid absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of developing hyponatremia and associated symptoms and complications (eg, nausea, cerebral edema) following transurethral resection (TUR) of the prostate or bladder or hysteroscopy is related to the rate, volume of absorption, osmolality, and volume of distribution of the nonconductive (ie, non-electrolyte) irrigation solution, and the rapidity of metabolism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    excretion of the solute and the water load [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/10,11,15,27-32\">",
"     10,11,15,27-32",
"    </a>",
"    ]. There is a direct correlation between the glycine deficit (the difference between the infused and collected volumes of the glycine irrigant) and the fall in serum sodium (",
"    <a class=\"graphic graphic_figure graphicRef74942 \" href=\"UTD.htm?43/28/44494\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The relationship between the glycine deficit and the reduction in serum sodium and the development of nausea and cerebral edema on computed tomography was illustrated in a study of 20 women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ten women who absorbed less than 500 mL of glycine irrigant had a mean decrease in serum sodium of 2.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      and did not have symptoms of hyponatremia or changes suggestive of cerebral edema on computed tomography.",
"     </li>",
"     <li>",
"      Six women who absorbed 1000 mL or more had a reduction in serum sodium of 13 to 25",
"      <span class=\"nowrap\">",
"       meq/L;",
"      </span>",
"      all had nausea and changes suggestive of cerebral edema on computed tomography.",
"     </li>",
"     <li>",
"      Four women absorbed 500 to 1000 mL of glycine irrigant; three had cerebral edema, two of whom had reductions in serum sodium of 10 and 13",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, a higher volume of irrigant fluid absorption is required to produce the same degree of hyponatremia in men who have a higher lean body weight and total body water than women (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The rate of fluid absorption is probably also an important factor in the development of hyponatremia. TUR and hysteroscopy procedures generally last for one hour or less, so fluid absorption is relatively rapid. One study suggested that a rate of fluid absorption in excess of 200 to 300 mL per 10 minutes is required to develop hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluid absorption thresholds at which the procedure should be halted are discussed below (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Halt procedure at absorption thresholds'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Time course of hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time course of the development of hyponatremia varies with the site of fluid absorption. Fluid absorbed into the vascular space (intravasation) rapidly lowers the serum sodium. This fluid presumably enters the vascular space directly through vessels opened during the procedure.",
"   </p>",
"   <p>",
"    The time course is more prolonged when perforation of a viscus during surgery leads to extravasation of irrigation fluid into the surrounding space. The serum sodium is usually lowest one to two hours after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/14\">",
"     14",
"    </a>",
"    ] and the degree of hyponatremia is only about one-third that expected from absorption directly into the vascular space [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/14,33\">",
"     14,33",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Subsequent events depend in part upon the irrigant used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glycine enters cells over several hours and, by four hours, glycine is almost equally distributed between the extracellular and intracellular compartments [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/31\">",
"       31",
"      </a>",
"      ]. Glycine entry into cells is associated with osmotic water movement from the extracellular fluid into the cells, which is probably responsible for the gradual increase in serum sodium that begins as soon as 10 to 20 minutes after the development of hyponatremia [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/11,28,31,34\">",
"       11,28,31,34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a series of 20 patients described above, the six patients with a glycine deficit (the difference between the infused and collected volumes of the glycine irrigant) of 1000 mL or more and two patients with a glycine deficit of about 700 mL had a decrease in serum sodium of 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or more [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/11\">",
"     11",
"    </a>",
"    ]. The mean fall in serum sodium was 16",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (141 to 125",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    immediately after surgery. The serum sodium then increased by a mean of 8.4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the first four hours after surgery, was stable for the next four hours, and then continued to increase toward baseline.",
"   </p>",
"   <p>",
"    Glycine is metabolized to serine, glyoxylate, ammonia, and other products and approximately 5 to 10 percent is excreted unchanged in the urine.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"       Sorbitol",
"      </a>",
"      is metabolized to glucose and fructose in the liver and then to carbon dioxide and water. Approximately 5 to 10 percent is excreted unchanged in the urine.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       Mannitol",
"      </a>",
"      does not enter cells and is not metabolized; it is excreted entirely in the urine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The urinary excretion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    and, to a much lesser degree, glycine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    creates an osmotic diuresis. The associated electrolyte-free water loss will raise the serum sodium concentration and the increase in sodium excretion will enhance correction of the volume overload [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Time course of osmolar shifts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum or plasma osmolality is normally determined by the sum of the osmotic contributions of the three major solutes in the plasma: sodium salts, glucose, and urea. The osmotic contributions of glucose and BUN to Posm are usually small. Thus, in the absence of diabetes mellitus or renal failure, the serum sodium concentration is the most important determinant of serum osmolality.",
"   </p>",
"   <p>",
"    These contributions are illustrated in the following formula, which can be used to estimate the serum osmolality (Sosm):",
"   </p>",
"   <p>",
"    &nbsp;Sosm &nbsp;= &nbsp;(2 &nbsp;x &nbsp;[serum Na+]) &nbsp;+ &nbsp;([serum",
"    <span class=\"nowrap\">",
"     glucose]/18)",
"    </span>",
"    &nbsp;+ &nbsp;(blood urea",
"    <span class=\"nowrap\">",
"     nitrogen/2.8)",
"    </span>",
"   </p>",
"   <p>",
"    The serum sodium is multiplied by two to account for the accompanying anion (chloride and bicarbonate) and the divisors 18 and 2.8 convert units of",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    into",
"    <span class=\"nowrap\">",
"     mosmol/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=see_link\">",
"     \"Serum osmolal gap\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with the serum sodium concentration, the serum osmolality varies over time following TUR or hysteroscopy. The hyponatremia associated with irrigation fluids is associated with a fall in serum osmolality that is less pronounced than with other etiologies of hyponatremia (eg, volume depletion, syndrome of inappropriate antidiuretic hormone secretion) or, in some cases, absent, due to presence of glycine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    in the extracellular fluid.",
"   </p>",
"   <p>",
"    Glycine (200",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    (165",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    solutions are hypoosmotic compared to the normal serum osmolality of 280 to 296",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    Thus, the initial serum osmolality will be reduced with retention of glycine, or sorbitol. In comparison, the 5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    solution is isosmotic and the initial serum osmolality will be relatively unchanged.",
"   </p>",
"   <p>",
"    With all three irrigation fluids, there will be a large serum (or plasma) osmolal gap due to the presence of the solute contained in the irrigant. The serum osmolal gap is equal to the difference between the measured serum osmolality, which will include the organic solute, and the serum osmolality estimated from the above formula, which does not include the irrigant solute. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=see_link\">",
"     \"Serum osmolal gap\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These relationships have been described during both TUR of the prostate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/34-39\">",
"     34-39",
"    </a>",
"    ] and hysteroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/30,31,40,41\">",
"     30,31,40,41",
"    </a>",
"    ]. In a prospective study of 100 patients who underwent TUR with glycine irrigant, for example, 10 patients developed neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/39\">",
"     39",
"    </a>",
"    ]. The mean serum sodium fell by an average of 17.7",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    which should have lowered the serum osmolality by about 35",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    However, the serum osmolality fell by only 11.4",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    due to the osmotic effect of glycine. The modest reduction in serum osmolality alone would not be expected to produce such marked neurologic symptoms (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Pathogenesis of neurologic symptoms'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The serum osmolal gap gradually disappears since glycine enters cells and is metabolized,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    is metabolized to carbon dioxide and water, and all three irrigants are excreted in the urine. As a result, the serum osmolality will gradually fall toward the level predicted from the serum sodium, glucose, and urea concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/31,42\">",
"     31,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One might expect the urine to be maximally dilute (less than 100",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    at this time to permit excretion of the excess water. However, most patients also have postoperative, stress-related release of antidiuretic hormone (ie, syndrome of inappropriate ADH secretion), which impairs water excretion and slows correction of the hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/43\">",
"     43",
"    </a>",
"    ]. Other factors that can impair urinary dilution are the associated osmotic diuresis, which, as mentioned above, is most pronounced and lasts for a longer time with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    irrigation, and possibly direct stimulation of antidiuretic hormone release by glycine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Time course of hyponatremia'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid overload and hyponatremia can be prevented by the following general measures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid the use of nonconductive (ie, non-electrolyte) irrigation fluids, if possible.",
"     </li>",
"     <li>",
"      Minimize fluid absorption by using low infusion pressures and limiting the duration of surgery.",
"     </li>",
"     <li>",
"      Monitor the quantity of fluid absorbed.",
"     </li>",
"     <li>",
"      Stop the procedure at predetermined absorption thresholds.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Avoid use of nonconductive irrigants",
"    </span>",
"    &nbsp;&mdash;&nbsp;When monopolar electrosurgery is used, nonconductive irrigation fluids are required to allow electrical energy to be focused and thereby avoid thermal burns. In contrast, bipolar systems permit the use of electrolyte solutions such as isotonic saline. These isosmotic fluids will reduce the risk of procedure-related hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/1-5,46-49\">",
"     1-5,46-49",
"    </a>",
"    ]. In a randomized trial of hysteroscopy in 200 postmenopausal women, for example, there was no reduction in serum sodium in the bipolar electrode group that used isotonic saline irrigant compared with a mean 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    reduction in serum sodium in the monopolar electrode group that used glycine irrigant [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis comparing monopolar versus bipolar TURP found that the bipolar technique eliminated the \"TURP syndrome\" and had a lower overall complication rate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/3\">",
"     3",
"    </a>",
"    ]. The mean fall in sodium concentration was 5.1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    with unipolar TURP and 1.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    with bipolar TURP, but this difference was not statistically significant. A subsequent international multicenter double-blind randomized controlled trial not included in this meta-analysis compared the perioperative efficacy and safety of bipolar versus monopolar techniques for TURP [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/4\">",
"     4",
"    </a>",
"    ]. Of the 295 patients enrolled, 279 underwent TURP, including 138 with monopolar and 141 with bipolar devices. In the bipolar group, the average fall in serum sodium was 0.8",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and the lowest serum sodium recorded in any patient was 131",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    In comparison, in the monopolar group, the average fall in serum sodium was 2.5",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and the lowest serum sodium recorded in any patient was 106",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Perioperative efficacy, safety, and secondary outcomes were otherwise comparable in the two groups. Other randomized trials have reported similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other energy sources, such as laser and microwave, also permit the use of electrolyte-containing irrigation fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Monitor fluid absorbed",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several methods can be used to monitor the amount of fluid absorbed during surgery so that patients at risk of severe hyponatremia can be detected. A direct approach is calculation of the fluid deficit (also called the glycine deficit), which is the difference between the volume of irrigation fluid administered and the volume removed by suction. Fluid is collected through suction tubing attached to the operative device (hysteroscope or cystoscope) and in plastic drapes beneath the patient.",
"   </p>",
"   <p>",
"    In hysteroscopy, the fluid deficit can be determined with an automated system or manually by the operating room staff. The automated system permits continuous measurement of the fluid deficit and intrauterine fluid pressure, titrates flow, and generates automatic alerts. An automated fluid pump and monitoring system is recommended by both the American College of Obstetricians and Gynecologists and the American Association of Gynecologic Laparoscopists [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. There are no similar guidelines for urologic procedures.",
"   </p>",
"   <p>",
"    With manual techniques, fluid is infused using the force of gravity (ie, elevating the infusion bag to different heights) or by inflating a large blood pressure cuff around the infusion bag. However, the effect of progressive elevation of the infusion bag on fluid absorption is not clear. In a study of 550 patients undergoing TUR of the prostate, there was no difference in fluid absorption within the range of 60 to 100 cm above the operating table [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A member of the surgical staff should be designated to measure the input and outflow and report the fluid deficit to the surgeon at regular intervals (eg, every 15 minutes). The accuracy of the volumetric method is reduced by two factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequent overfilling of the infusion bags by the manufacturer by 3 to 6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During TUR of the prostate, the accuracy of volumetric balance is diminished because of a higher degree of admixture with blood in the irrigating fluid returns, more frequent spillage on the floor, and urinary excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternative techniques for monitoring fluid absorption include gravimetric weighing of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/53\">",
"     53",
"    </a>",
"    ] and the respiratory output of tracer quantities of either ethanol or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    that have been added to the irrigation fluid, a technique that is not commonly used in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/52,54-56\">",
"     52,54-56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Halt procedure at absorption thresholds",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, serious complications of absorption of nonconductive irrigation fluids occur in most women who absorb more than 1000 mL, with a higher absorption threshold for men (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Volume and rate of fluid absorption'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    To minimize the risk of hyponatremia, we suggest the following fluid absorption thresholds for women undergoing hysteroscopy using nonconductive (ie, non-electrolyte) irrigation solutions. These are in keeping with the 2005 American College of Gynecology technology assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 750 mL fluid deficit represents excessive fluid absorption. The surgical team should temporarily halt the procedure. The fluid inflow should be stopped, suction should remain on to assist with fluid removal, and a sample sent for urgent measurement of serum sodium (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Evaluation'",
"      </a>",
"      below). Assessment of mental status should be performed when possible, but may be limited in patients under anesthesia. Once this information is available, a decision can be made to resume surgery for as short a period as possible or to terminate the procedure.",
"     </li>",
"     <li>",
"      At a 1000 to 1500 mL fluid deficit (depending in part upon patient size), the surgical team should TERMINATE the procedure as quickly as possible, and the serum sodium concentration and mental status should be closely monitored. Many gynecologic surgeons plan to finish the case at a fluid deficit of 1000 mL, and immediately terminate the procedure at a fluid deficit of 1500 mL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Higher fluid absorption thresholds, 1000 mL to temporarily halt the procedure and 2000 mL to terminate the procedure, have been suggested for TUR of the prostate. This approach is based in part upon an analysis of 273 patients who received glycine irrigant [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/57\">",
"     57",
"    </a>",
"    ]. Symptoms of TUR syndrome (eg, nausea, vomiting, confusion,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypotension) increased significantly when fluid absorption exceeded 1000 mL. The average number of such symptoms was 2.3, 3.1, and 5.8 per procedure with fluid absorption between 1000 and 2000 mL, between 2000 mL and 3000 mL, and more than 3000 mL, respectively. Symptoms developed more often 30 to 60 min postoperatively than during the surgical procedure (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Clinical manifestations'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The higher thresholds for fluid absorption in men reflect at least in part the greater lean body weight and therefore total body water in men. As a result, more fluid must be absorbed in men to produce the same reduction in serum sodium (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Patients who are treated with saline irrigant (as with bipolar electrosurgery) have much less risk for hyponatremia, but can develop heart failure. The 2005 American College of Gynecology technology assessment recommends that the surgical team",
"    <strong>",
"     terminate",
"    </strong>",
"    the procedure as quickly as possible and that irrigant infusion be discontinued if fluid absorption reaches 2500 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Minimize fluid pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The movement of irrigating fluid into blood vessels (intravasation) begins when the fluid pressure exceeds the venous pressure (about 10 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/15\">",
"     15",
"    </a>",
"    ]. However, transurethral resection and hysteroscopy procedures occur within hollow organs. As a result, the pressure threshold for fluid absorption is best measured as the pressure within the operative site (prostate, bladder, or uterus). When this threshold is reached, fluid is absorbed through open, low-pressure venous channels or perforations induced by resection and, at high pressures, into tissue compartments. Irrigant absorption begins at intrauterine pressures of 70 mmHg or greater [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/58,59\">",
"     58,59",
"    </a>",
"    ] and bladder pressures greater than 15 to 25 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/60-63\">",
"     60-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Limit operation time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimizing the duration of surgery is another approach to limiting fluid absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Although there are no definitive data that have established an operative time threshold beyond which excessive fluid is predictably absorbed, we suggest that after one hour of surgery, the patient's overall status, the volume of fluid absorbed, and the anticipated time to completion of surgery be reassessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest symptom of hyponatremia associated with glycine irrigation is nausea, which commonly occurs when the serum sodium concentration has fallen by 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or more. This typically requires fluid absorption of at least 1000 mL in women undergoing hysteroscopy (",
"    <a class=\"graphic graphic_figure graphicRef74942 \" href=\"UTD.htm?43/28/44494\">",
"     figure 1",
"    </a>",
"    ) and a higher value in men undergoing TUR of the prostate (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    More severe hyponatremia, which has been associated with glycine irrigant absorption rates as high as 2000 to 3000 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/57\">",
"     57",
"    </a>",
"    ], can be associated with confusion, disorientation, twitching, seizures, and hypotension, and transient visual abnormalities, such as decreased visual acuity or blurred vision [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/37,64-66\">",
"     37,64-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     Sorbitol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    irrigation fluids are used less frequently. Compared to glycine irrigation, symptoms induced by excessive fluid absorption are similar with sorbitol irrigation (except for the lack of visual abnormalities) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/29\">",
"     29",
"    </a>",
"    ] and significantly less prominent with mannitol irrigation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Absorption of large volumes of irrigation fluid can also cause expansion of the extracellular fluid and pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pathogenesis of neurologic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;When acute hyponatremia occurs as a result of other etiologies (such as primary polydipsia, use of ecstasy), it is associated with acute hypoosmolality corresponding to the degree of hyponatremia. This acute hypoosmolality is associated with acute cerebral edema. The cerebral edema is due to a water shift into the brain from the hypotonic extracellular fluid and is thought to play a central etiologic role in the neurologic symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the pathogenesis of neurologic symptoms following the absorption of non-electrolyte irrigation fluids is less well-defined. As mentioned in the preceding section, the hyponatremia associated with nonconductive (ie, non-electrolyte) irrigation fluids is associated with a less pronounced or no fall in serum osmolality due to the presence of glycine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    in the irrigation fluid and the extracellular fluid. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Time course of osmolar shifts'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22951?source=see_link\">",
"     \"Hysteroscopy: Managing fluid and gas distending media\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, factors other than hypoosmolality and cerebral edema may cause the neurologic symptoms that often develop when treatment with non-electrolyte irrigation fluids generates marked hyponatremia. The very low serum sodium concentration itself, glycine toxicity, and the accumulation of ammonia, serine,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glyoxylate (all generated by the metabolism of glycine) may be responsible [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/35-37,70-72\">",
"     35-37,70-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in experimental animals and humans are consistent with the hypothesis that multiple factors contribute to the toxicity of glycine and that neither hypoosmolality nor cerebral edema is essential for the development of neurologic symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a rat model, the mortality associated with extreme glycine-induced hyponatremia (90 to 95",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      was not reduced when the serum osmolality was maintained with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another rat model, isoosmolar or hypoosmolar glycine infusions produced minimal cerebral edema even after glycine had equilibrated across most cell membranes [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although cerebral edema has been reported in a series of women who developed nausea following exposure to glycine irrigant, the findings were subtle [",
"      <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/11\">",
"       11",
"      </a>",
"      ]. The diagnosis of cerebral edema was based upon careful acute and post recovery computed tomography scans, and the diagnosis of cerebral edema could not have been made in any patient without this comparison.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glycine and some of its metabolites may also have neurotoxicity. One such metabolite that accumulates in some patients exposed to glycine irrigant is ammonia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. The postoperative mental status of two patients who became comatose following TURP correlated more closely with the serum ammonia concentration than the serum sodium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/72\">",
"     72",
"    </a>",
"    ]. However, the majority of patients undergoing TUR have a minimal or no increase in blood ammonia despite substantial absorption of glycine irrigant [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glycine itself is an inhibitory transmitter in the central nervous system, especially the spinal cord, brainstem, and retina [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/75\">",
"     75",
"    </a>",
"    ]. Glycine may be responsible for self-limited visual abnormalities including decreased visual acuity, blurred vision, and blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/64-66\">",
"     64-66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia should be suspected whenever large volumes of nonconductive (ie, non-electrolyte) irrigation fluids have been used, when operative time is prolonged (both of which promote excessive fluid absorption), or when patients develop new neurologic symptoms during postoperative recovery. The risk of neurologic symptoms is greatest when fluid absorption exceeds 1000 mL. In such patients, the serum sodium and osmolality should be urgently measured (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Volume and rate of fluid absorption'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The difference between the measured and calculated osmolalities (osmolal gap) reflects the concentration of the",
"    <span class=\"nowrap\">",
"     infused/absorbed",
"    </span>",
"    irrigant and its non-ionized metabolites. The calculated serum osmolality is estimated from the following formula:",
"   </p>",
"   <p>",
"    &nbsp;Calculated Sosm &nbsp; = &nbsp; (2 x serum [Na]) &nbsp;+ &nbsp;",
"    <span class=\"nowrap\">",
"     [Glucose]/18",
"    </span>",
"    &nbsp;+ &nbsp;",
"    <span class=\"nowrap\">",
"     BUN/2.8",
"    </span>",
"   </p>",
"   <p>",
"    The serum osmolal gap, which is normally less than 5 to 10",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    can exceed 30 to 60",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    immediately following transurethral resection or hysteroscopy due to the transient accumulation of glycine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/31,36\">",
"     31,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=see_link\">",
"     \"Serum osmolal gap\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of hyponatremia following TUR, hysteroscopy, and some other procedures such as percutaneous nephrolithotomy is directed by the patient&rsquo;s clinical condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Asymptomatic hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific therapy is",
"    <strong>",
"     not",
"    </strong>",
"    necessary for asymptomatic hyponatremia or, when symptoms cannot be assessed because of anesthesia, for a serum sodium reduction of 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or less (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Clinical manifestations'",
"    </a>",
"    above). If renal function is adequate, then the excretion of the excess water and metabolism and excretion of the infused non-electrolyte solute will rapidly correct the hyponatremia. A loop diuretic can be given if the patient has signs of pulmonary congestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Symptomatic hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal therapy of patients with symptomatic hyponatremia varies with the serum sodium concentration, measured serum osmolality, and the volume status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Role of hypertonic saline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertonic saline is indicated in symptomatic patients with marked hyponatremia who have a substantially reduced serum osmolality or cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/37,38,40\">",
"     37,38,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential value of hypertonic saline in hyponatremic patients with substantial hypoosmolality was illustrated in a retrospective study of 18 patients who underwent TUR or hysteroscopy and developed symptomatic hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/38\">",
"     38",
"    </a>",
"    ]. The mean serum sodium was 106",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and the mean serum osmolality was 235",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    with a serum glycine of 18",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (equivalent to 18",
"    <span class=\"nowrap\">",
"     mosmol/kg),",
"    </span>",
"    a value significantly lower than reported in other cases of glycine-induced hyponatremia of this severity (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Time course of osmolar shifts'",
"    </a>",
"    above). Fourteen patients were treated with hypertonic saline and survived; neither the saline dose nor the rate of correction was reported. The other four patients were not treated with hypertonic saline and had a respiratory arrest and died even though the hyponatremia was less severe than in the survivors.",
"   </p>",
"   <p>",
"    When hypertonic saline is given, we prefer the regimen that has been recommended for the treatment of exercise-associated hyponatremia, another cause of acute hyponatremia. The patient is initially given 100 mL of 3 percent saline as a bolus, which provides 51 meq of sodium and should acutely raise the serum sodium concentration by 2 to 3",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    If the neurologic symptoms do not improve, a 100 mL bolus of 3 percent saline can be given one or two more times at 10-minute intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1706?source=see_link&amp;anchor=H19#H19\">",
"     \"Exercise-associated hyponatremia\", section on 'Use of hypertonic saline'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the treatment of hyponatremia\", section on 'Severe symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapid correction of hyponatremia and hypoosmolality is probably safe following TUR or hysteroscopy. Because of the extremely short duration of hyponatremia, there has not been time for the cerebral adaptations that put patients with chronic hyponatremia at risk for osmotic demyelination if the serum sodium is raised too quickly. Nevertheless, the American College of Obstetricians and Gynecologists guidelines concluded that the serum sodium should not be raised by more than 12",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the first 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/40\">",
"     40",
"    </a>",
"    ]. The rate of correction should be slower (8 to 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    maximum increase in the first 24 hours) in patients who present with hyponatremia more than 48 hours after the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the treatment of hyponatremia\", section on 'Rate of correction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H8#H8\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Osmotic demyelination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, optimal therapy has not been defined in symptomatic patients who have severe hyponatremia, but a normal or near normal serum osmolality (eg, greater than 270",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/37\">",
"     37",
"    </a>",
"    ]. In this setting, hypertonic saline is of unproven benefit, will raise the serum osmolality above the normal range, and has been associated with the delayed development of osmotic demyelination in at least one case report [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/77\">",
"     77",
"    </a>",
"    ]. Hypertonic saline should probably",
"    <strong>",
"     not",
"    </strong>",
"    be used in such patients and hemodialysis may be the safest approach [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Role of hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis will rapidly correct hyponatremia, osmotic derangements, volume expansion, and also remove the non-electrolyte solute and its toxic metabolites (glycine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    ). It has been used in symptomatic patients with severe renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/36\">",
"     36",
"    </a>",
"    ] and in patients with severe neurologic symptoms, marked hyponatremia, and normal or only slightly reduced serum osmolality (which will be associated with a high serum osmolal gap) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Loop diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absorption of large volumes of irrigation fluid can cause expansion of the extracellular fluid and pulmonary edema in patients undergoing transurethral resection or hysteroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Loop diuretics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ) can be given to treat fluid overload. However, loop diuretics should",
"    <strong>",
"     not",
"    </strong>",
"    be given in the absence of volume overload since they can reduce the effective intravascular volume and, as shown in two small randomized trials of patients undergoing TUR of the prostate, may contribute to the development of hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Possible role of surgical drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed, perforation of a viscus during surgery can result in rapid extravasation of irrigation fluid into the surrounding space, and absorption of this fluid into the circulation can generate and contribute to persistence of, hyponatremia (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Drainage of this fluid from the perivesical or peritoneal space might help treat the hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/80\">",
"     80",
"    </a>",
"    ]. However, in a small series (eight patients), suprapubic drainage did not improve the hyponatremia and was associated with prolongation of hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?8/41/8858/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transurethral resection (TUR) of the prostate or bladder, a variety of hysteroscopy procedures, and certain other percutaneous procedures (such as percutaneous nephrolithotomy) may use large volume irrigation with nonconductive (ie, non-electrolyte) fluids to avoid thermal burns. Absorption of these irrigation fluids produces hyponatremia with varying degrees of hypoosmolality. Neurologic manifestations can occur when fluid absorption exceeds 500 mL and particularly 1000 mL. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      These problems can be avoided with bipolar electrosurgery, which permits the use of isotonic saline irrigation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Avoid use of nonconductive irrigants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Irrigant-associated hyponatremia can be prevented or minimized by reducing fluid absorption. This is accomplished with the use of low infusion pressures, limitation of surgery duration, by monitoring the degree of fluid absorption, and by aborting the procedure at prespecified absorption thresholds. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Monitor fluid absorbed'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a nonconductive solution is used, we suggest the use of an automated rather than a manual fluid monitoring system (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) and we recommend terminating the procedure if the fluid deficit reaches 1000 to 1500 mL in women (depending in part upon patient size) and 2000 mL in men (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Halt procedure at absorption thresholds'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of hyponatremia include nausea and malaise. This may be followed by headache, lethargy, and obtundation, and eventually renal failure, seizures, coma and respiratory arrest. Patients exposed to glycine irrigant may complain of visual deficits or blindness. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of patients who become symptomatic during or following one of these procedures, as well as the evaluation of all patients who have had prolonged surgery or a large volume of fluid absorbed includes measurement of the plasma sodium and osmolality and calculation of the plasma osmolal gap. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend no specific therapy for asymptomatic hyponatremia or, when symptoms cannot be assessed because of anesthesia, for a serum sodium reduction of 5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or less (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Asymptomatic hyponatremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptoms of hyponatremia and reduced plasma osmolality, we recommend treatment with hypertonic saline (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest that 3 percent saline be given as a 100 mL (1.5 to 2",
"      <span class=\"nowrap\">",
"       mL/kg)",
"      </span>",
"      bolus that can be repeated twice at 10-minute intervals, if necessary (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The efficacy and safety of such therapy is uncertain in hyponatremic patients who have a normal or near normal serum osmolality (eg, greater than 275",
"      <span class=\"nowrap\">",
"       mosmol/kg).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Role of hypertonic saline'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is little concern about overly rapid correction of the hyponatremia following TUR or hysteroscopy due to the extremely short duration of the hyponatremia. However, hyponatremia should not be overcorrected. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Symptomatic hyponatremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe renal dysfunction and those with the combination of severe symptoms, marked hyponatremia, and a normal or near normal serum osmolality (eg, greater than 275",
"      <span class=\"nowrap\">",
"       mosmol/kg),",
"      </span>",
"      we suggest urgent hemodialysis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Role of hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients in whom major fluid absorption occurs following intraoperative perforation of the uterus, bladder, or prostatic fossa, surgical drainage is an option to remove the deposited fluid. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Possible role of surgical drainage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/1\">",
"      Zeltser I, Pearle MS, Bagley DH. Saline is our friend. Urology 2009; 74:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/2\">",
"      Mohta M, Bhagchandani T, Tyagi A, et al. Haemodynamic, electrolyte and metabolic changes during percutaneous nephrolithotomy. Int Urol Nephrol 2008; 40:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/3\">",
"      Issa MM. Technological advances in transurethral resection of the prostate: bipolar versus monopolar TURP. J Endourol 2008; 22:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/4\">",
"      Mamoulakis C, Skolarikos A, Schulze M, et al. Results from an international multicentre double-blind randomized controlled trial on the perioperative efficacy and safety of bipolar vs monopolar transurethral resection of the prostate. BJU Int 2012; 109:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/5\">",
"      Michielsen DP, Coomans D, Braeckman JG, Umbrain V. Bipolar transurethral resection in saline: the solution to avoid hyponatraemia and transurethral resection syndrome. Scand J Urol Nephrol 2010; 44:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/6\">",
"      Mebust WK, Holtgrewe HL, Cockett AT, et al. Transurethral prostatectomy: immediate and postoperative complications. Cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol, 141: 243-247, 1989. J Urol 2002; 167:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/7\">",
"      Aydeniz B, Gruber IV, Schauf B, et al. A multicenter survey of complications associated with 21,676 operative hysteroscopies. Eur J Obstet Gynecol Reprod Biol 2002; 104:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/8\">",
"      Jansen FW, Vredevoogd CB, van Ulzen K, et al. Complications of hysteroscopy: a prospective, multicenter study. Obstet Gynecol 2000; 96:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/9\">",
"      Atici S, Zeren S, Ariboan A. Hormonal and hemodynamic changes during percutaneous nephrolithotomy. Int Urol Nephrol 2001; 32:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/10\">",
"      Istre O, Skajaa K, Schjoensby AP, Forman A. Changes in serum electrolytes after transcervical resection of endometrium and submucous fibroids with use of glycine 1.5% for uterine irrigation. Obstet Gynecol 1992; 80:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/11\">",
"      Istre O, Bjoennes J, Naess R, et al. Postoperative cerebral oedema after transcervical endometrial resection and uterine irrigation with 1.5% glycine. Lancet 1994; 344:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/12\">",
"      Olsson J, Hahn RG. Ethanol monitoring of irrigating fluid absorption in transcervical resection of the endometrium. Acta Anaesthesiol Scand 1995; 39:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/13\">",
"      Hahn RG, Stalberg HP, Ekengren J, Rundgren M. Effects of 1.5% glycine solution with and without 1% ethanol on the fluid balance in elderly men. Acta Anaesthesiol Scand 1991; 35:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/14\">",
"      Hahn RG. Transurethral resection syndrome from extravascular absorption of irrigating fluid. Scand J Urol Nephrol 1993; 27:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/15\">",
"      Hahn RG. Fluid absorption in endoscopic surgery. Br J Anaesth 2006; 96:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/16\">",
"      Hahn RG. Transurethral resection syndrome after transurethral resection of bladder tumours. Can J Anaesth 1995; 42:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/17\">",
"      Dorotta I, Basali A, Ritchey M, et al. Transurethral resection syndrome after bladder perforation. Anesth Analg 2003; 97:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/18\">",
"      Olsson J, Berglund L, Hahn RG. Irrigating fluid absorption from the intact uterus. Br J Obstet Gynaecol 1996; 103:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/19\">",
"      Paschopoulos M, Polyzos NP, Lavasidis LG, et al. Safety issues of hysteroscopic surgery. Ann N Y Acad Sci 2006; 1092:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/20\">",
"      Corson SL, Brooks PG, Serden SP, et al. Effects of vasopressin administration during hysteroscopic surgery. J Reprod Med 1994; 39:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/21\">",
"      Hahn RG, Ekengren JC. Patterns of irrigating fluid absorption during transurethral resection of the prostate as indicated by ethanol. J Urol 1993; 149:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/22\">",
"      Goldenberg M, Cohen SB, Etchin A, et al. A randomized prospective comparative study of general versus epidural anesthesia for transcervical hysteroscopic endometrial resection. Am J Obstet Gynecol 2001; 184:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/23\">",
"      Bergeron ME, Beaudet C, Bujold E, et al. Glycine absorption in operative hysteroscopy: the impact of anesthesia. Am J Obstet Gynecol 2009; 200:331.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/24\">",
"      Goldenberg M, Zolti M, Bider D, et al. The effect of intracervical vasopressin on the systemic absorption of glycine during hysteroscopic endometrial ablation. Obstet Gynecol 1996; 87:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/25\">",
"      Sharma DP, Harvey AB. Does intraprostatic vasopressin prevent the transurethral resection syndrome? BJU Int 2000; 86:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/26\">",
"      Hahn RG. Smoking increases the risk of large scale fluid absorption during transurethral prostatic resection. J Urol 2001; 166:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/27\">",
"      Rhymer JC, Bell TJ, Perry KC, Ward JP. Hyponatraemia following transurethral resection of the prostate. Br J Urol 1985; 57:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/28\">",
"      Hahn RG. Relations between irrigant absorption rate and hyponatraemia during transurethral resection of the prostate. Acta Anaesthesiol Scand 1988; 32:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/29\">",
"      Inman RD, Hussain Z, Elves AW, et al. A comparison of 1.5% glycine and 2.7% sorbitol-0.5% mannitol irrigants during transurethral prostate resection. J Urol 2001; 166:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/30\">",
"      Phillips DR, Milim SJ, Nathanson HG, et al. Preventing hyponatremic encephalopathy: comparison of serum sodium and osmolality during operative hysteroscopy with 5.0% mannitol and 1.5% glycine distention media. J Am Assoc Gynecol Laparosc 1997; 4:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/31\">",
"      Gonzales R, Brensilver JM, Rovinsky JJ. Posthysteroscopic hyponatremia. Am J Kidney Dis 1994; 23:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/32\">",
"      Barisic, D, Wamsteker, K, Strelec, M, et al. The effect of sorbitol&ndash;mannitol absorption on serum sodium concentration during hysteroscopic surgery. Gynaecol Endosc 1996; 5:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/33\">",
"      Olsson J, Hahn RG. Simulated intraperitoneal absorption of irrigating fluid. Acta Obstet Gynecol Scand 1995; 74:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/34\">",
"      Silver SM, Kozlowski SA, Baer JE, et al. Glycine-induced hyponatremia in the rat: a model of post-prostatectomy syndrome. Kidney Int 1995; 47:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/35\">",
"      Sunderrajan S, Bauer JH, Vopat RL, et al. Posttransurethral prostatic resection hyponatremic syndrome: case report and review of the literature. Am J Kidney Dis 1984; 4:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/36\">",
"      Campbell HT, Fincher ME, Sklar AH. Severe hyponatremia without severe hypoosmolality following transurethral resection of the prostate (TURP) in end-stage renal disease. Am J Kidney Dis 1988; 12:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/37\">",
"      Agarwal R, Emmett M. The post-transurethral resection of prostate syndrome: therapeutic proposals. Am J Kidney Dis 1994; 24:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/38\">",
"      Ayus JC, Arieff AI. Glycine-induced hypo-osmolar hyponatremia. Arch Intern Med 1997; 157:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/39\">",
"      Ghanem AN, Ward JP. Osmotic and metabolic sequelae of volumetric overload in relation to the TUR syndrome. Br J Urol 1990; 66:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/40\">",
"      American College of Obstetricians and Gynecologists. ACOG technology assessment in obstetrics and gynecology, number 4, August 2005: hysteroscopy. Obstet Gynecol 2005; 106:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/41\">",
"      Loffer FD, Bradley LD, Brill AI, et al. Hysteroscopic fluid monitoring guidelines. The ad hoc committee on hysteroscopic training guidelines of the American Association of Gynecologic Laparoscopists. J Am Assoc Gynecol Laparosc 2000; 7:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/42\">",
"      BEIRNE GJ, MADSEN PO, BURNS RO. SERUM ELECTROLYTE AND OSMOLALITY CHANGES FOLLOWING TRANSURETHRAL RESECTION OF THE PROSTATE. J Urol 1965; 93:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/43\">",
"      Agraharkar M, Agraharkar A. Posthysteroscopic hyponatremia: evidence for a multifactorial cause. Am J Kidney Dis 1997; 30:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/44\">",
"      Hahn RG, Rundgren M. Vasopressin responses during transurethral resection of the prostate. Br J Anaesth 1989; 63:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/45\">",
"      Rundgren M, Hjelmqvist H, Gunnarsson U, Hahn RG. Intracerebroventricular infusion of glycine stimulates vasopressin release in conscious sheep. Neuroreport 1993; 4:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/46\">",
"      Issa MM, Young MR, Bullock AR, et al. Dilutional hyponatremia of TURP syndrome: a historical event in the 21st century. Urology 2004; 64:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/47\">",
"      Berg A, Sandvik L, Langebrekke A, Istre O. A randomized trial comparing monopolar electrodes using glycine 1.5% with two different types of bipolar electrodes (TCRis, Versapoint) using saline, in hysteroscopic surgery. Fertil Steril 2009; 91:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/48\">",
"      Michielsen DP, Debacker T, De Boe V, et al. Bipolar transurethral resection in saline--an alternative surgical treatment for bladder outlet obstruction? J Urol 2007; 178:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/49\">",
"      Gilleran JP, Thaly RK, Chernoff AM. Rapid communication: bipolar PlasmaKinetic transurethral resection of the prostate: reliable training vehicle for today's urology residents. J Endourol 2006; 20:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/50\">",
"      Hahn RG, Ekengren J. Absorption of irrigating fluid and height of fluid bag during transurethral resection of the prostate. Br J Urol 1993; 72:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/51\">",
"      Nezhat CH, Fisher DT, Datta S. Investigation of often-reported ten percent hysteroscopy fluid overfill: is this accurate? J Minim Invasive Gynecol 2007; 14:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/52\">",
"      Hahn RG. The volumetric fluid balance as a measure of fluid absorption during transurethral resection of the prostate. Eur J Anaesthesiol 2000; 17:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/53\">",
"      Shipstone DP, Inman RD, Beacock CJ, Coppinger SW. Validation of the ethanol breath test and on-table weighing to measure irrigating fluid absorption during transurethral prostatectomy. BJU Int 2002; 90:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/54\">",
"      Hahn RG. Ethanol monitoring of irrigating fluid absorption. Eur J Anaesthesiol 1996; 13:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/55\">",
"      Hahn RG. Prevention of TUR syndrome by detection of trace ethanol in the expired breath. Anaesthesia 1990; 45:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/56\">",
"      Drobin D, Hjelmqvist H, Piros D, Hahn RG. Monitoring of fluid absorption with nitrous oxide during transurethral resection of the prostate. Acta Anaesthesiol Scand 2008; 52:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/57\">",
"      Olsson J, Nilsson A, Hahn RG. Symptoms of the transurethral resection syndrome using glycine as the irrigant. J Urol 1995; 154:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/58\">",
"      Shirk GJ, Gimpelson RJ. Control of intrauterine fluid pressure during operative hysteroscopy. J Am Assoc Gynecol Laparosc 1994; 1:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/59\">",
"      Hasham F, Garry R, Kokri MS, Mooney P. Fluid absorption during laser ablation of the endometrium in the treatment of menorrhagia. Br J Anaesth 1992; 68:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/60\">",
"      Gray RA, Lynch C, Hehir M, Worsley M. Intravesical pressure and the TUR syndrome. Anaesthesia 2001; 56:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/61\">",
"      Madsen PO, Naber KG. The importance of the pressure in the prostatic fossa and absorption of irrigating fluid during transurethral resection of the prostate. J Urol 1973; 109:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/62\">",
"      Hult&eacute;n J. Prevention of irrigating fluid absorption during transurethral resection of the prostate. Scand J Urol Nephrol Suppl 1984; 82:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/63\">",
"      Hahn RG. Intravesical pressure during irrigating fluid absorption in transurethral resection of the prostate. Scand J Urol Nephrol 2000; 34:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/64\">",
"      Mizutani AR, Parker J, Katz J, Schmidt J. Visual disturbances, serum glycine levels and transurethral resection of the prostate. J Urol 1990; 144:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/65\">",
"      Radziwill AJ, Vuadens P, Borruat FX, Bogousslavsky J. Visual disturbances and transurethral resection of the prostate: the TURP syndrome. Eur Neurol 1997; 38:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/66\">",
"      Karci A, Erkin Y. Transient blindness following hysteroscopy. J Int Med Res 2003; 31:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/67\">",
"      Hahn RG, Sandfeldt L, Nyman CR. Double-blind randomized study of symptoms associated with absorption of glycine 1.5% or mannitol 3% during transurethral resection of the prostate. J Urol 1998; 160:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/68\">",
"      Witz CA, Silverberg KM, Burns WN, et al. Complications associated with the absorption of hysteroscopic fluid media. Fertil Steril 1993; 60:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/69\">",
"      Wang JH, He Q, Liu YL, Hahn RG. Pulmonary edema in the transurethral resection syndrome induced with mannitol 5%. Acta Anaesthesiol Scand 2009; 53:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/70\">",
"      Bernstein GT, Loughlin KR, Gittes RF. The physiologic basis of the TUR syndrome. J Surg Res 1989; 46:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/71\">",
"      Istre O, Jellum E, Skajaa K, Forman A. Changes in amino acids, ammonium, and coagulation factors after transcervical resection of the endometrium with a glycine solution used for uterine irrigation. Am J Obstet Gynecol 1995; 172:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/72\">",
"      Ryder KW, Olson JF, Kahnoski RJ, et al. Hyperammonemia after transurethral resection of the prostate: a report of 2 cases. J Urol 1984; 132:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/73\">",
"      Hahn RG, Sandfeldt L. Blood ammonia levels after intravenous infusion of glycine solution with and without ethanol. Scand J Urol Nephrol 1999; 33:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/74\">",
"      Hahn RG. Blood ammonia concentrations resulting from absorption of irrigating fluid containing glycine and ethanol during transurethral resection of the prostate. Scand J Urol Nephrol 1991; 25:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/75\">",
"      Vaney DI, Nelson JC, Pow DV. Neurotransmitter coupling through gap junctions in the retina. J Neurosci 1998; 18:10594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/76\">",
"      Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol 2009; 29:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/77\">",
"      Weissman JD, Weissman BM. Pontine myelinolysis and delayed encephalopathy following the rapid correction of acute hyponatremia. Arch Neurol 1989; 46:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/78\">",
"      Donatucci CF, Deshon GE Jr, Wade CE, Hunt M. Furosemide-induced disturbances of renal function in patients undergoing TURP. Urology 1990; 35:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/79\">",
"      Crowley K, Clarkson K, Hannon V, et al. Diuretics after transurethral prostatectomy: a double-blind controlled trial comparing frusemide and mannitol. Br J Anaesth 1990; 65:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/41/8858/abstract/80\">",
"      Montesinos Baillo A, Ban&uacute;s Gassol JM, Palou Redorta J, et al. Physiopathology and surgical treatment of extravasated peritoneal fluid after transurethral resection. Eur Urol 1984; 10:183.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2363 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-A318AF7B5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8858=[""].join("\n");
var outline_f8_41_8858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONCONDUCTIVE IRRIGATION FLUIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS OF HYPONATREMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Volume and rate of fluid absorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Time course of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Time course of osmolar shifts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Avoid use of nonconductive irrigants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Monitor fluid absorbed",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Halt procedure at absorption thresholds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Minimize fluid pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Limit operation time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pathogenesis of neurologic symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Asymptomatic hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Symptomatic hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Role of hypertonic saline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Role of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Loop diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Possible role of surgical drainage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2363\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2363|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/28/44494\" title=\"figure 1\">",
"      Glycine deficit serum Na",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1706?source=related_link\">",
"      Exercise-associated hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22951?source=related_link\">",
"      Hysteroscopy: Managing fluid and gas distending media",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=related_link\">",
"      Overview of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=related_link\">",
"      Serum osmolal gap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=related_link\">",
"      Surgical and other invasive therapies of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_41_8859="Lispro insulin and blood glucose";
var content_f8_41_8859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lispro insulin and blood glucose",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Blood glucose level, mg/dL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lispro insulin, units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7 am",
"       </td>",
"       <td>",
"        50 to 250",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Noon",
"       </td>",
"       <td>",
"        70 to 200",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 pm",
"       </td>",
"       <td>",
"        50 to 250",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 pm",
"       </td>",
"       <td>",
"        100 to 200",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bedtime",
"       </td>",
"       <td>",
"        100 to 200",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8859=[""].join("\n");
var outline_f8_41_8859=null;
var title_f8_41_8860="Aspiration pneumonia categories";
var content_f8_41_8860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of aspiration pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Inoculum",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pulmonary sequelae",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acid",
"       </td>",
"       <td>",
"        Chemical pneumonitis",
"       </td>",
"       <td>",
"        <p>",
"         Acute dyspnea, tachpnea, tachycardia; &plusmn; cyanosis, bronchospasm, fever",
"        </p>",
"        <p>",
"         Sputum: pink, frothy",
"        </p>",
"        <p>",
"         Radiograph: infiltrates in one or both lower lobes",
"        </p>",
"        <p>",
"         Hypoxemia",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Positive pressure breathing",
"        </p>",
"        <p>",
"         Intravenous fluids",
"        </p>",
"        <p>",
"         Tracheal suction",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oropharyngeal bacteria",
"       </td>",
"       <td>",
"        Bacterial infection",
"       </td>",
"       <td>",
"        <p>",
"         Usually insidious onset",
"        </p>",
"        <p>",
"         Cough, fever, purulent sputum",
"        </p>",
"        <p>",
"         Radiograph: infiltrate involving dependent pulmonary segment or lobe &plusmn; cavitation",
"        </p>",
"       </td>",
"       <td>",
"        Antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inert fluids",
"       </td>",
"       <td>",
"        <p>",
"         Mechanical obstruction",
"        </p>",
"        <p>",
"         Reflex airway closure",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Acute dyspnea, cyanosis &plusmn; apnea",
"        </p>",
"        <p>",
"         Pulmonary edema",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Tracheal suction",
"        </p>",
"        <p>",
"         Intermittent positive-pressure breathing with oxygen and isoproterenol",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Particulate matter",
"       </td>",
"       <td>",
"        Mechanical obstruction",
"       </td>",
"       <td>",
"        Dependent upon level of obstruction, ranging from acute apnea and rapid death to irritative chronic cough &plusmn; recurrent infections",
"       </td>",
"       <td>",
"        <p>",
"         Extraction of particulate matter",
"        </p>",
"        <p>",
"         Antibiotics for superimposed infection",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8860=[""].join("\n");
var outline_f8_41_8860=null;
var title_f8_41_8861="Homesickness prevention for hospitalized children";
var content_f8_41_8861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Homesickness-prevention strategies for parents of hospitalized children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Homesickness is normal. Almost all children feel a bit sad and nervous when they are separated from home and loved ones. No matter how turbulent your child's life has been lately, he or she is likely to miss many things about home during this hospitalization. One way that parents can help children deal with this distress is to reassure them that missing home is normal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Talk with your child honestly about when and why he or she is being hospitalized. Although the honest truth may be upsetting or surprising to some children, coping with the reality of their situation now prevents uncomfortable surprises later. Children who feel \"tricked\" into hospitalization lose confidence in the reliability of their caregivers and therapists, which increases homesickness.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. To help your child feel \"at home\" in the hospital, the staff may give your child a tour of the unit. Staff members can explain the daily routine on the unit and answer any questions that you or your child might have. This orientation, along with photographs, calendars, schedules, and introductions to other children, will help your child feel more comfortable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Although you may have some mixed feelings about your child's hospitalization, try not to convey those feelings to your child. If you talk about your mixed feelings, you may increase your child's own doubts about the value of hospitalization. Instead, give your child a consistent, positive message about why he or she is here. Help your child understand the value of this hospital stay.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Often, it is impossible for staff to predict your child's exact discharge date. This date depends on many factors, some of which are constantly changing. Although this uncertainty is hard for families, it is even harder when an exact date does not work out as planned. The disappointment of a postponed discharge date can make children quite homesick. Therefore, instead of focusing on a particular date, ask the staff to estimate a range of dates, and be honest with your child that no one knows the exact discharge date yet.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Sometimes, children in the hospital get confused about time. Your child might even forget when you visited the last time or when you said you would come back for a visit. This confusion can make homesickness worse. To help your child keep track of your visits, draw or buy a simple calendar and write your plans down. Try your best to be on time for the visits and telephone calls that you plan.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Frequent visits and telephone calls help ease children's homesickness. Of course, you have other commitments, but try to visit as often as possible. Avoid canceling visits at the last moment, which is particularly upsetting to children. If you cannot visit, be sure to call and talk with your child on the telephone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        8. Despite all of your efforts and all of the staff's efforts to make children feel comfortable, many of them still feel homesick in the hospital. Fortunately, many children can help themselves feel better by doing one of the things below. You and the hospital staff should share these techniques with your child:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        a. Do a fun activity to forget about missing home. Play a game with a friend, watch television, listen to music, or read a book.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        b. Do something to feel closer to home. Write a letter, talk on the telephone, or look at a family picture.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        c. Think about the good side of being in the hospital. There are kids to play with and staff to help you. Being in the hospital will help you get better.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        d. Keep a positive attitude. Staff members can answer your questions and teach you a lot about dealing with your problems.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        e. Remind yourself that you will be home soon. Hospitalizations do not last forever.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        f. Talk with someone who can make you feel better, such as your doctor or one of the other staff members.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Thurber CA, Walton E, the Council on School Health. Preventing and treating homesickness. Pediatrics 2007; 119:192. Copyright &copy; 2007 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8861=[""].join("\n");
var outline_f8_41_8861=null;
var title_f8_41_8862="Regulation of ADH release II";
var content_f8_41_8862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interaction of volume with osmoregulation of ADH",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 180px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The influence of hemodynamic status on the osmoregulation of ADH in otherwise healthy humans. The numbers in the center circles refer to the percentage change in volume or pressure; N refers to the normovolemic normotensive subject. Notice that the hemodynamic status affects both the slope of the relationship between the plasma ADH and osmolality and the osmotic threshold for ADH release.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Robertson, GL, Shelton, RL, Athar, S, Kidney Int 1976; 10:25. Reprinted by permission from Kidney International.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8862=[""].join("\n");
var outline_f8_41_8862=null;
var title_f8_41_8863="Peripheral nerve stimulator";
var content_f8_41_8863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Monitoring of neuromuscular blockade",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 148px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To monitor degree of neuromuscular blockade, two small conducting pads are placed over the distribution of the ulnar nerve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Isenstein, DA, Venner, DS, Duggan, J, Chest 1992; 102:1258.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_41_8863=[""].join("\n");
var outline_f8_41_8863=null;
